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Background: Phenylketonuria (PKU) is one of the most common inherited metabolic 
disorders and the first to be included on newborn screening. Even treated, it can impact quality of 
life (QoL) due to strict dietary management and potential for neuropsychiatric symptoms including 
anxiety, depression, and impaired executive functioning and attention. This study aims to learn 
about the impact the newest treatment for PKU – pegvaliase, an enzyme substitution therapy – has 
on QoL and to assess the residual support and resource needs of patients taking it. In clinical trials, 
pegvaliase was shown to improve certain neuropsychiatric symptoms. No research is currently 
published on the impact of pegvaliase on overall QoL or residual support and resource needs.  
Methods: Adults who have PKU were surveyed, including adults who are and are not 
taking pegvaliase. Survey questions assessed current management, overall QoL, QoL PKU-
related, and currently utilized resources and supports and remaining needs. Standardized questions 
assessing depression and cognition were also included. Responses were compared by whether the 
respondent was taking pegvaliase and whether their phe levels were above or below a set threshold.  
Results: Significant differences were found in satisfaction with management, impact of 
PKU, general satisfaction with life, and cognition when comparing by phe level. When comparing 
by pegvaliase status, a significant difference was only found in satisfaction with management. 
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Residual resource and support needs predominantly involved social, financial, and adult-specific 
needs, although many respondents reported utilizing supports or resources in these domains. 
Conclusions: The knowledge gained by this study is relevant to public health and genetic 
counseling by adding to the existing literature on QoL related to PKU, specifically related to use 
of pegvaliase and phe levels. Phe level seemed to have the most robust impact on QoL, although 
pegvaliase use was shown to improve QoL to a degree – likely related to its ability to lower phe 
levels. PKU-related worries seem to have a similar impact on QoL regardless of management, and 
should be a focus for future care. Ensuring that adult patients are aware of available supports and 
resources is also important in filling residual needs reported in this study. 
vi 
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1.0 Introduction 
Phenylketonuria (PKU) is one of the most common inherited metabolic disorders, with an 
estimated incidence of 1 in 15,0001. It was the first condition to be included in newborn screening 
programs, following development of an assay by Guthrie and Susi in 1963 that could be conducted 
on a dried blood spot2. PKU is part of a group of conditions titled hyperphenylalaninemia, all of 
which are characterized by elevated levels of the essential amino acid phenylalanine (phe). 
Severity of hyperphenylalaninemia in the context of PKU can be separated into three categories: 
classical PKU (phe concentrations greater than 1,200 μmol/L), mild PKU (phe concentrations 
between 600 to 1,200 μmol/L) and non-PKU hyperphenylalaninemia (phe concentrations between 
120 to 600 μmol/L)1. PKU is inherited in an autosomal recessive pattern due to pathogenic variants 
in PAH, which encodes phenylalanine hydroxylase (PAH) – the enzyme responsible for converting 
phe to tyrosine in humans1. Over 1,100 different pathogenic variants have been reported to date3. 
with some correlation between variant type and severity of PAH deficiency4–6.  
When untreated, classic PKU causes a range of symptoms including intellectual 
disabilities, seizures, and impaired motor skills7,8. With the advent of newborn screening, early 
treatment can be initiated to prevent or mitigate these symptoms, however certain symptoms such 
as anxiety and depression, attention and executive functioning deficits, and lower IQ (but not 
usually to the extent of intellectual disability) may continue even with appropriate treatment9–14. 
Treatment for PKU originally relied solely on dietary restriction of protein, and therefore of phe, 
supplemented by medical formulas that contain all amino acids except phe, and other essential 
nutrients15. These dietary restrictions were once only routinely followed during childhood16,17, but 
treatment for life has been the standard recommendation in the United States since 200016. 
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Management options for PKU have expanded in recent years. In 2008 an oral therapy, 
sapropterin dihydrochloride (Kuvan, BioMarin Pharmaceuticals), a synthetic form of 
tetrahydrobiopterin (BH4) – a cofactor of PAH, was approved by the FDA18. This therapy 
successfully lowers phe levels in many people who have mild PKU, but it typically does not 
provide a clinical benefit to people who have more severe, classical PKU6,18,19. Several studies 
have been conducted to measure the impact this therapy had on the quality of life of patients who 
responded to the medication. These studies largely found that there was not a significant increase 
in quality of life subsequent to treatment with sapropterin and the associated relaxation of dietary 
restrictions, with only one study showing an improvement in multiple domains of quality of 
life11,20–22. Notably, the study that showed improvements in quality of life was also the only one to 
use a quality of life questionnaire specific to PKU;  this questionnaire was adapted for use in the 
current study. It has also been postulated that improvements in quality of life due to dietary 
relaxation for some patients following treatment with sapropterin may be limited, since these 
patients typically have a less stringent diet at baseline compared with people who have more severe 
or classic PKU21–24. It therefore can be postulated that patients who have more severe PKU may 
experience a greater improvement in quality of life following an effective treatment that allows for 
dietary relaxation. 
In 2018, the newest management option for PKU, and the first to be effective for a 
substantial portion of adults who have classical PKU, was approved by the FDA. Pegvaliase 
(Palynziq, BioMarin Pharmaceuticals) is an injectable enzyme substitution therapy using 
recombinant phenylalanine ammonia lyase, a bacteria-derived enzyme that converts phe to 
cinnamic acid and ammonia25. It has been shown to be useful in lowering phe levels for adult 
patients with phe levels over 600μmol/L25–29. As this is a more recently approved therapy for PKU, 
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many studies have been published on the effectiveness and safety of pegvaliase from a clinical 
standpoint, including improvement of neuropsychiatric symptoms26,30,31. However, no studies on 
the impact it has had on quality of life for individuals taking it have been published to date.  
Research into treatments for PKU, including gene therapies, is currently ongoing. If these 
therapies are proved to be safe and effective and receive FDA-approval, their impact on quality of 
life and residual needs will be an interesting area for future research projects. However, as these 
therapies are still in development, they will not be discussed in detail here. 
 
The specific aims for this study were to use an online questionnaire to: 
1. Assess residual effects of PKU in adult patients taking pegvaliase, focusing on 
psychosocial impact, including neuropsychiatric symptoms, and related quality of life. 
2. Evaluate how dietary decision-making has been impacted for PKU patients taking 
pegvaliase and how this has affected their quality of life. 
3. Identify potential residual resource and support needs for adult patients with PKU taking 
pegvaliase, stratified by geographic area based on the reported zip code of the clinic they 
attend. 
 
This questionnaire was open to all adults who have PKU, including adults who are taking 
pegvaliase as well as adults who are not taking it. Forty-three eligible adults responded to the 
survey, contributing to current knowledge surrounding the impact of PKU and pegvaliase on 
quality of life. By learning more about how a treatment like pegvaliase can impact a patient’s life 
beyond lowering their phe levels, providers can continue to improve overall care for these 
individuals. These continued improvements may include providing anticipatory guidance on the 
4 




2.0 Literature Review 
2.1 Background on PKU 
Phenylketonuria (PKU) is an inborn error of metabolism that is inherited in an autosomal 
recessive pattern. With an estimated prevalence of 1 in 15,000 in the United States, it is one of the 
most common inherited metabolic disorders. PKU is caused by mutations in phenylalanine 
hydroxylase (PAH).  PAH is responsible for converting phenylalanine (phe) to tyrosine. When 
PAH function is impaired, as in PKU, phe accumulates to toxic levels in both the blood and the 
brain1. Untreated, this leads to an array of clinical presentations including intellectual disability, 
seizures, and impaired motor skills7,8. 
PKU is part of a larger catergory of inborn errors of metabolism – hyperphenylalaninemias 
(HPA) – which are all characterized by increased levels of phe in the blood. While most of these 
conditions are caused by deleterious mutations of varying severity in PAH, a small subset 
(approximately 1-2%) of cases of hyperphenylalaninemia are caused by deficiencies in other 
enzymes responsible for either the synthesis or regeneration of tetrahydrobiopterin (BH4), a key 
cofactor of PAH1. GTP cyclohydrase I (GTPCH) and 6-pyruvoyl-tetrahydropterin synthase 
(PTPS) are the enzymes involved in synthesis of BH4, and pterin-4a-carbinolamine dehydratase 
(PCD) and dihydropteridine reductase (DHPR) are the enzymes involved in BH4 regeneration32. 
Even within PKU due to PAH mutations, there are multiple sub-types defined by the 
severity of the phenotype that are delineated by blood phe concentration. Normal reference blood 
phe concentrations are between 50 and 110 μmol/L1. Classical PKU is the most common of these 
sub-types and is the most severe with phe concentrations greater than 1,200 μmol/L1,33. It is 
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followed by mild PKU with concentrations ranging from 600 to 1,200 μmol/L, and non-PKU mild 
hyperphenylalaninemia (mHPA) with concentrations ranging from 120 to 600 μmol/L1. These 
differences among sub-types are largely due to differences in PAH activity, as influenced by the 
PAH mutations present. Specifically, the average PAH activity in each of these sub-types has been 
estimated to be 51.7% (compared to wild type levels) in mHPA, 40.4% in mild PKU and 3.8% in 
classic PKU34.  
2.1.1 Genotype-Phenotype Correlations 
To date, over 1,100 mutations in PAH have been reported3. This large number of mutations 
is associated with the phenotypic heterogeneity seen within PKU, as different mutations within 
PAH lead to the wide range in severity of PAH dysfunction and deficiency and thereby affect 
clinical presentation4,5. 
Although there is an established correlation between genotype relative to PAH and PKU 
phenotype, it is not a perfect correlation. Studies focused on genotype-phenotype predictions have 
consistently predicted a majority of participants’ phenotypes based on their genotypes, but there 
are always discrepancies in the remaining individuals4–6. Most people who have the same genotype 
will have the same phenotype. However, several cases have been reported where this is not true. 
Certain mutations have been reported in all three phenotypes or only in the highly dissimilar 
classical PKU and mHPA5,6. Although such discrepancies are more common in patients with 
identical heteroallelic genotypes, patients with identical homoallelic genotypes have also been 
clinically classified with different sub-types of PKU5. While a small number of these discrepancies 
may be explained by possible clinical misclassification, it is more likely that a combinations of 
other factors such as activity level of BH4 or epigenetics are influencing phenotype along with 
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PAH mutations35,36. Interallelic complementation – a phenomenon where compound heterozygous 
genotypes produce a more or less severe phenotype than would be expected in the homozygous 
form of either mutation – must also be considered due to PAH being a tetramer. This phenomenon 
could play a role in the approximately 76% of people who have PKU who have a heteroallelic 
PAH genotype37.  
Even though there is not a perfect correlation between genotype and severity of PKU, a 
person’s genotype can still be informative in estimating PAH activity4–6. It is therefore important 
to establish a patient’s genotype because level of PAH activity can influence treatment approach. 
This is because the severity of PAH mutations influences dietary management due to differences 
in phe tolerance, as well as the types of pharmaceutical treatments available to a patient. People 
who have mild or moderate PKU are more likely to respond to an oral treatment, sapropterin, while 
people who have classic PKU may instead be candidates for an injectable treatment, pegvaliase36. 
Both of these treatment approaches will be discussed in more detail in later sections. 
2.1.2 Neuropsychological Presentation 
An increased prevalence of a wide range of neuropsychiatric disorders has been reported 
in adults who have PKU when compared with the general population and when compared to people 
who have diabetes mellitus10. In this study, people who have diabetes mellitus were included to 
capture differences in mental health that may come with managing a chronic metabolic disease. 
The results of this study found that even among adults 20 to 39 years old who would have received 
recommendations to follow treatment for life, there were higher rates of intellectual disability and 
autism spectrum disorder, as well as eating disorders, OCD, and ADHD10. In contrast, other studies 
examining the intellectual abilities of people who have early-treated PKU do not report higher 
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rates of intellectual disabilities among these individuals, suggesting that people who have early-
treated PKU typically have an IQ within normal range. However, studies do often report that 
people who have PKU have lower IQs when compared to controls11,13,14. Reports of increased rates 
of intellectual disability in people who were diagnosed when lifetime treatment was recommended 
may be explained by variation in treatment history of these individuals9. A separate publication 
reported increased rates of anxiety disorders among people who have PKU when compared to both 
the general population and people who have diabetes, and increased rates of depression when 
compared to the general population, but not the diabetes cohort10. Although there are increased 
rates of depression and anxiety among adults who have PKU and follow treatment-for-life 
guidelines, these rates are further increased among adults who have PKU but have discontinued 
treatment since childhood12. 
People who have PKU also often have impaired executive functioning. Executive function 
involves several cognitive tasks: 1) working, or short-term, memory, 2) inhibitory control, the 
ability to prevent unnecessary or irrelevant information from preventing one from reaching a 
specific goal, 3) cognitive flexibility, the ability to effectively switch between tasks with different 
goals, and 4) organization and planning. Of these, cognitive flexibility and organization and 
planning tend to be more complex to measure38. Bilder et al (2016) reported deficits in attention, 
inhibitory control, and cognitive flexibility, but not working memory, when people who have 
early-treated PKU were compared to members of the general population9. Feldmann et al (2019), 
also found a significant difference between healthy controls and people who have early-treated 
PKU in regard to attention, but only when comparing older adults who have PKU (over age 42), 
not younger adults who have PKU, to healthy controls11. Similarly, they reported deficits in 
information processing speeds among older adults who have PKU11. Differences between older 
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and younger early treated individuals is potentially due to the length of time that has passed since 
discontinuing or relaxing treatment in adulthood, if this was done11. Regarding working memory, 
there is mixed evidence of working memory being largely comparable between children who have 
early-treated PKU and healthy controls, with the treated individuals becoming impaired to varying 
degrees as they age38. 
Similar findings were identified by a meta-analysis of studies examining previously 
published papers comparing people who have PKU and controls regarding executive functioning 
and other neuropsychological tasks such as attention maintenance. The meta-analysis found that 
people who have PKU tend to perform poorly compared to controls on tests of information 
processing speed, attention, inhibitory control and motor control, but reported no significant 
impairement of working memory13. 
Social functioning is another important aspect of cognitive function that can be affected by 
increased phe levels through its detrimental impact on serotonin and dopamine levels. Jahja et al 
(2016) measured the ability of people who have PKU and healthy controls to exhibit necessary 
social skills such as facial and emotional recognition and Theory of Mind (identifying and 
understanding the feelings and thoughts of other people). They found that people who have PKU 
begin to have less developed social skills compared to their peers in the general population starting 
in adolescence (age 12), with these social impairments increasing over time. Higher lifetime phe 
levels, but not current levels, were similarly associated with poorer social skills beginning in 
adolescence39. 
2.1.2.1 Biological Mechanism of Neuropsychological Presentation 
There are multiple ways that PAH deficiency can lead to an impact on neuropsychological 
functioning. In addition to increased phe levels being potentially toxic to the brain, PAH deficiency 
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limits the amount of tyrosine that crosses the blood-brain barrier (BBB). This happens in two ways: 
1) lower tyrosine levels due to PAH having limited ability or inability or convert phe to tyrosine, 
and 2) phe competing with tyrosine to cross the BBB and crossing more successfully than tyrosine 
and other large neutral amino acids (LNAAs), such as tryptophan, especially when phe levels are 
increased1,40,41. LNAAs are key precursors for neurotransmitters, with tyrosine and tryptophan 
being precursors for dopamine and serotonin, respectively30,40. By inhibiting LNAAs from 
crossing the BBB, cerebral protein synthesis – a process that is crucial to cognitive development 
during childhood and early adulthood as well as cognitive functioning throughout a person’s 
lifetime – is also impaired41. Elevated phe can also interfere with cholesterol production which can 
in turn impact neurotransmitter production40. 
These neurochemical changes can be linked to the neuropsychiatric presentation of PKU.  
Executive function impairments and ADHD can be related to the impact of increased phe levels 
on dopamine production. These functions are primarily carried out by the prefontal cortex, an area 
of the brain that relies heavily on the presence of dopamine30,38. Increased phe levels can also 
impact levels of glutamate, another important neurotransmitter that has been linked to memory, 
depression and anxiety, as well as norepinephrine, which has been linked to inattention and 
ADHD30,40. Decreased serotonin can be related to sleep disorders and depression, both of which 
can be seen in people with PKU30. 
There are also structural differences that can be linked to the neuropsychiatric presentation 
in PKU. White matter abnormalities, detected as hyperintensities on MRI, have been extensively 
studied in people who have PKU. These abnormalitites are present in the majority of both early 
and late treated individuals who have PKU, including those who currently have well-controlled 
phe levels11,14,42–44. Subcortical and periventricular areas, especially the frontal and occipital-
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parietal lobes, are the most commonly affected14,42–44. Early studies correlated the degree of 
abnormality with recent phe levels, with some studies reporting the best correlation with current 
phe levels42,44,45 and others reporting the best correlation with cumulative phe over the past few 
years14. Length of time on a relaxed or unrestricted diet may also play a role in these white matter 
abnormalities independent of recent phe levels43,44. 
In contrast, more recent studies that use diffuse tensor imaging (DTI), a newer MRI 
scanning technique, often find correlations between degree of microstructural white matter 
abnormality and historical phe levels or lifetime phe exposure. One such study reported the 
strongest correlation with white matter abnormality was phe level at diagnosis, not recent phe 
levels, although current phe levels were also correlated43. Another study using DTI with children 
who have PKU found correlations between microstructural white matter abnormalities and lifetime 
phe exposure and mean phe levels over time. In this study, children who had more severe 
microstructural abnormalities were more likely to have experienced high or variable phe levels 
throughout their lives46. Similarly, a different study involving early treated children who had phe 
levels under 600μmol/L found that children with higher past and current phe levels typically had 
greater microstructural abnormalities and reported that this trend increased with time47. 
 There are few established correlations between degree of microstructueral abnormality 
and neurological function, with most studies, including a study using DTI47, being unable to find 
correlations with IQ or other neurological symptoms of PKU14,42,44. One study that used DTI with 
people who had early-treated PKU did find a correlation between microstructural white matter 
abnormalities and IQ, as well as executive function tasks, including working memory45. 
One proposed theory regarding these white matter abnormalities is that they are related to 
reversible altered myelination because of their close relationship to recent phe levels, compared to 
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historical phe levels14,42,44,45. Data from DTI studies can also been interpreted as suggestive of 
abnormal myelination47. The altered myelination theory is supported by studies that show 
abnormal myelination in patients who have untreated PKU. This impaired myelination may be due 
to impaired cholesterol synthesis and can lead to impaired dopamine synthesis, further decreasing 
dopamine levels in people who have PKU40. Alternative theories include accumulation of water 
inside cells due to excess of hydrophilic metabolites or cellular debris43,45. 
2.2 Newborn Screening & PKU 
In 1963, Robert Guthrie and Ada Susi published a method to test newborns for PKU using 
a bacterial inhibition assay with dried blood spot on a filter paper card2. This assay began newborn 
screening. Since then, numerous other screening methods have been developed for a variety of 
diseases48. 
Newborn screening (NBS) practices are determined on a state-by-state basis, leading to 
variability in the number of conditions for which screening is conducted and the methodologies 
used. Further, states vary in their ability to support patients diagnosed following NBS, including 
the availability of treatment and management services due to a lack of specialists knowledgeable 
about these rare conditions in certain areas of the country. This in turn creates the potential for 
health disparities among these patients49.  
In 2006, a list of conditions recommended to be included on NBS nationwide was 
assembled and published by the American College of Medical Genetics (ACMG) at the request of 
the Maternal and Child Health Bureau within the federal Health Resources and Services 
Administration (HRSA). This request was in response to a statement by the American Academy 
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of Pediatrics Newborn Screening Task Force providing evidence that having a nationally 
standardized screening process would be beneficial to both patients and the public health system 
as a whole49. The list produced by ACMG was labled the Recommended Uniform Screening Panel 
(RUSP) and included 29 conditions which should, at minimum, be part of each state’s NBS 
program49. This list has now been expanded to 36 conditions50. The criteria for inclusion in the 
RUSP are: 1) availability of an appropriately sensitive and specific test for the condition that can 
be used within 24 to 48 hours of birth, 2) established benefits for early detection and early 
intervention or treatment, 3) availability of treatment and care by appropriate specialists, 4) burden 
of the condition, including severity of the phenotype and incidence, and 5) understanding of the 
natural history of the condition, especially in regard to how it affects newborns. The cost of adding 
a condition to NBS was also considered, but was not used as a primary criterion due to its 
subjective nature49.  
PKU was one of the highest scoring conditions included on this panel. This is because 1) 
testing has been available since the 1960s, 2) there is substantial evidence for the benefits of early 
treatment to minimize the effects of what would othersise be a devastating disorder, 3) treatment 
is readily available in the form of dietary management, and 4) the condition has a relatively high 
incidence. By beginning dietary management for PKU in the first two weeks of life, overall 
cognitive outcomes for the patient are significantly improved51, providing a prime example of the 
beneftis of NBS.  Even in the early years following the development of a newborn screening 
method for PKU by Guthrie and Susi, significant improvements in detection rate and age of 
diagnosis were noted. This was especially true in states like California which adopted mandatory 
screening during the 1960s7. 
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2.3 Management of PKU 
Current guidelines for management of PKU, as established by the American College of 
Medical Genetics and Genomics (ACMG), state that the goal for blood phe concentration in 
patients who have PKU is 120 to 360μmol/L. However, levels below this range may not be 
considered too low as long as they occur in the presence of relatively high phe intake and do not 
fall below 30μmol/L. To achieve this, dietary management beginning in the first week of life is 
recommended for infants who have a blood phe level of over 600μmol/L, with the intent to have 
phe levels in the target range by the second week of life. Treatment should then be continued for 
life15. 
Management recommendations for women who have PKU before and during pregnancy 
are slightly different. This is because of the teratogenic effect of elevated phe, referred to as 
maternal PKU syndrome. Maternal PKU syndrome has been shown to cause microcephaly, 
intrauterine growth restriction, congenital heart defects, and low IQ. With the exception of 
congenital heart defects, which are only related to elevated phe levels prior to eight to ten weeks 
of gestation due to the timing of fetal heart development, the likelihood and severity of these 
symptoms have a direct relationship to both the degree of phe elevation and the length of time the 
fetus was exposed to elevated phe levels. Guidelines in the United States recommend a stricter 
goal for blood phe levels of 60 to 360μmol/L, with the best outcomes associated with achieving a 
phe level below 360μmol/L prior to pregnancy. International guidelines are more strict and 
recommend phe levels under 240μmol/L during pregnancy15.  
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2.3.1 Historical Management Approaches 
The benefits of a low-phe diet in people who have PKU were first reported in 195352. 
Initiation of a low-phe diet as soon as possible following a diagnosis of PKU has been 
recommended since this discovery. A 1978 survey assessing the practices and recommendations 
of 72 PKU clinics throughout the United States found that about half of children were 
discontinuing diet by age 7, with 8 clinics recommending discontinuation at or before age 6, one 
of which recommended discontinuation at age 3. Only 16 of the 72 clinics were recommending 
treatment for life, although about a quarter of clinics surveys indicated that they were considering 
recommended discontinuing diet at a later age than they were currently17. This inconsistency 
among clinics at the time of the survey was likely due to the conflicting evidence of the impact of 
dietary discontinuation. Many of the clinics with either a later recommended age of discontinuation 
or recommendation of treatment for life had experience with patients who had been negatively 
impacted by discontinuing diet, while many of the clinics who recommended earlier 
discontinuation did not report having similar experiences17. This set the stage for an increasing 
number of clinics recommending treatment for life throughout the 1980s. By the 1990s, treatment 
for life was a commonplace recommendation made by PKU clinics in the United States16. This 
shift was supported by a paper published in 1991 with evidence to support a negative impact of 
dietary discontinuation as late as age 10, and further suggested that dietary discontinuation in 
adulthood after full brain maturation would have a similar, although attenuated, impact53.  
However, the first nationwide recommendation for treatment for life was not released until 
the early 2000s16,54. The implications of maternal PKU syndrome were factored into this 
recommendation due to the increased difficulty of regaining metabolic control prior to conception 
and maintaining metabolic control throughout pregnancy when a low-phe diet had been previously 
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discontinued16. These original guidelines included more lenient blood phe levels than those 
recommended in the current guidelines as follows: 120 to 360μmol/L for infants and children under 
the age of 12, 120 to 600μmol/L from age 12 through adolescence, and 120 to 900μmol/L for 
adults16. Previously, it was not uncommon for clinics to allow relaxation of diet after age 6, as the 
brain was thought to be essentially fully developed by this time55. 
2.3.2 Dietary Management for PKU 
Many people who have PKU have to follow a strict low-phe diet in order to reach the target 
range of 120 to 360 μmol/L for blood phe levels. This involves a diet that is low in natural protein 
yet contains an adequate amount of phe, an essential amino acid, for normal growth and 
development. The amount of natural protein and overall amount of phe a person can consume and 
still maintain the target range varies from patient to patient depending on their residual PAH 
activity and their current stage of life. Careful monitoring of protein and phe intake to consume 
only what is needed can be achieved by use of specialized low-phe and phe-free medical foods 
and beverages and by tracking phe exhanges throughout the day15. A single phe exchange consists 
of 15mg of phe, which equates to approximately 0.3 grams of protein when using an average of 
50mg of phe per 1g of protein56. Patients may also use foods that are modified to have lower 
protein levels while maintaining a similar taste and appearance to their natural, high-protein 
equivalents15. 
Consistent monitoring of blood phe levels is critical to fine-tuning the recommended 
dietary management for each individual patient. The recommended frequency of blood phe 
monitoring varies over a persons lifetime, being most frequent in infancy (weekly) and decreasing 
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in frequency over time until adulthood (monthly). More frequent monitoring may be necessary if 
a patient is not well-controlled or during certain life events, such as growth spurts or pregnancy15. 
2.3.3 Adherence to Management Recommendations 
Adherence to management recommendations over time is critical for the overall health of 
a person who has PKU. As described above, uncontrolled PKU after childhood can lead to various 
neuropsychiatric impacts, including impaired executive functioning skills. These skills, such as 
the ability to plan for the future and self-monitor, are necessary for a patient to follow a regular 
dietary schedule. Therefore, when a patient stops following management guidelines, the associated 
decline in exectutive functioning skills can make it more difficult for the patient to go back on diet 
and adhere to management recommendations in the future15. Treatment for life is also beneficial 
in this sense as the continuous metabolic control is entails can mitigate these neuropsychiatric 
impacts15. Similarly, it has been shown that it is difficult for women who have discontinued diet 
to achieve the recommended phe level prior to conception and maintain it throughout 
pregnancy15,16. This makes treatment for life a way to limit the effects of maternal PKU by 
encouraging women who have PKU to have good metabolic control throughout the lifespan, as is 
recommended for all people who have PKU, allowing metabolic control during pregnancy to be 
more achievable.   
Measurement of blood phe levels is the standard method to monitor and assess metabolic 
control and, in turn, dietary adherence51,57,58. Using phe level measurements, it has been repeatedly 
shown that adherence to diet and control of blood phe levels tend to decrease after childhood51,58,59. 
A meta-analysis of publications comparing people who have different sub-types of PKU (mHPA, 
mild PKU, or classical PKU) studying blood phe levels in relation to clinical outcomes reported 
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27% of young children (ages 0 to 6) having phe levels that exceed the recommended threshold, 
compared to 78% of patients over the age of 1858. Similar findings were reported by a 2015 survey 
distributed by the National PKU Alliance (NPKUA), with only a quarter of patients under 18 
exceeding the recommended range, compared to almost two-thirds of adult patients, even though 
68.4% of patients (all ages) reported that they wanted to have phe levels within the recommended 
range60. This trend is also present in regard to patients becoming increasingly lost to follow up as 
they age, with adults being more likely to be lost to follow up than children. Over half of adults 
over 30 years old were lost to follow up compared to approximately 10 percent of children ages 0-
451. However, compared to historical levels, blood phe levels in patients on diet are on average 
lower now than they were in the past51,59. 
Supporting the linkage between increasing phe levels and  changes in compliance with age, 
a study focusing only on adolescents and adults who have PKU found that 75% of their participants 
reported following their dietitian’s recommendations about using their protein substitute. 
However, only about 50% of their participants reported being “on diet”61. Further, 56% of their 
participants reported measuring their blood phe levels as often as their doctor recommended and 
only 41% of participants reported weighing or measuring their phe exchanges all the time or most 
of the time61. The majority of their participants had a strong understanding of each of these 
recommendations, yet this knowledge did not lead to reliable adherence to these 
recommendations61. Their findings regarding continuation of diet into adulthood were similar to 
the results of a study in the United Kingdom which showed that 46% of their participants were 
continuting to follow the recommended diet into adulthood. This study also found the majority of 
adults who discontinued the diet never resumed dietary management. This was especially true for 
males, possibly because of strict dietary management for women before and during pregnancy62. 
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The results also revealed that 89% of their participants who reported being on diet were receiving 
less than the recommended amount of amino acid supplement, with over half (55%) receiving less 
than 25% of their recommended amino acid supplements. This is in contrast to the substantially 
higher numbers reported by Durham-Shearer et al61,62. 
There are several nuances to using phe level statistics to estimate overall adherence. These 
statistics typically come from clinical data, leaving the possibility that patients who are lost to 
follow up, and therefore potentially not following management recommendations, may have 
significantly higher phe levels than those reported in published studies51. This is supported by data 
from the 2015 NPKUA survey, which found that 58% of patients who have phe levels within 
recommended range had been seen in a clinic within the last 12 months, compared to only 38.6% 
of patients who had not been seen in a clinic for at least 12 months60. A subset of patients who 
follow with clinics and know their phe levels are higher than recommended may manipulate when 
they test their phe levels to make them appear consistently lower. An example of this would be 
waiting to do their test until they know their phe intake is lower instead of measuring at regular 
intervals51,57. 
2.3.3.1 Barriers to Adherence 
There are a number of barriers that can make it difficult for a person who has PKU to 
adhere to management recommendations. Some of these barriers are related to clinical services, as 
patients, especially adult patients, may have difficulty accessing a clinic with providers who are 
knowledgeable about PKU, especially in rural areas59, although recent increases in telemedicine 
usage may help diminish the impact of distance. A recent survey based in Michigan reported that, 
on average, patients had to spend over 4 hours in travel time to get to and from their metabolic 
clinic appointments63. Additionally, a survey based in Colorado reported patients travelling 
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anywhere from 5 to 584 miles to their clinic, with an average of 136 miles59. This barrier is 
exacerbated in some cases because not every clinic sees adult patients. This can be compounded 
by the fact that some patients would rather continue to follow at the clinic where they were treated 
as a child and are not comfortable seeking care elsewhere. Alternatively, not all people who have 
PKU will feel comfortable seeking care at a clinic based at a pediatric center, even when the clinic 
sees both pediatric and adult patients55. 
There is also the issue of access to medical foods, which can be costly especially when 
following a low-phe diet for life. The average annual cost of medical foods for people who have 
PKU in the United States is estimated at $6,400 for children and $9,000 for adults. These cost 
numbers become even more substantial when considering that they are limited to medical foods 
alone and do not include other PKU-related costs such as pharmaceutical treatments or co-pays 
and travel costs of attending clinic visits. The cost of these medical foods makes it difficult for 
people who have PKU to obtain them. Sixty-percent of parents and 68% of adults reported that it 
was difficult to obtain the necessary medical foods, with the cost of purchasing them being a major 
factor, especially among parents63. Ideally, people who have PKU would have consistent insurance 
coverage for these low-protein modified foods and low-phe medical formulas that are crucial to 
adhering to dietary management guidelines. However, over 20% of states do not require insurance 
coverage for any medical foods, low-protein foods or formulas, for patients of any age. Several 
other states mandate coverage, but only for children, not adults, despite treatment-for-life 
guidelines. There are also several states that only mandate coverage for either medical formulas or 
low-protein foods, not both55. Even when insurance coverage of one or both categories is available, 
there are often stipulations that is has to be prescribed to the patient or that the patient must have 
a feeding tube to use with the medical formula, which is not necessary for people consuming 
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medical formula for PKU15. Currently, the only consistency among states is that Medicaid provides 
coverage for medical foods. It is a complex process to apply for Medicaid though, which poses 
another barrier, especially since Medicaid is typically reserved for children, those who have 
significant disabilities, or people who have low-income, which is not the case for all people who 
have PKU55. 
The Medical Nutrition Equity Act (S.3657), a bill that was introduced to the Senate in 
2020, may help address some barriers related to insurance coverage if it is passed into law. In its 
current form, it would do so by expanding coverage of medically necessary foods under Medicare, 
Medicaid, and private insurance, as well as redefining medically necessary foods to include both 
low-protein modified foods and medical foods or formulas not requiring a prescription64. 
Companies who produce medical foods also recognize the difficulty of gaining insurance coverage 
for these medically necessary products. Many such companies offer free assistance in navigating 
insurance to help patients and families obtain coverage for this reason65–67. 
Cost barriers may also be partially alleviated by private assistance programs. BioMarin, 
the company that produces both of the pharmaceutical treatments for PKU, offers a co-pay 
assistance program for eligible patients to help minimize the costs of these treatments. However, 
this is only available to patients who have commercial insurance, leaving some people who have 
PKU ineligible for this assistance regardless of income 68,69. The National Organization of Rare 
Disorders (NORD) also provides financial assistance to patients and families with qualifying 
income levels to help with the cost of managing PKU including clinic visits and medical foods, as 
well as pharmaceuticals70. 
Time commitment required to prepare low phe foods, including weighing and calculating 
phe exchanges throughout the day, is also a barrier for some individuals63,71. This time 
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commitment has been estimated to be 300 hours a year (0.9 hours a day)63. This can be especially 
problematic when factoring in demanding work schedules for adult patients71. The social burden 
of adhering to a PKU diet, including preparing and packing separate low-phe meals to eat at social 
events and potential harassment by other attendees for doing so, is also a key factor that has been 
reported as making it difficult to follow diet, mainly among adult patients63,71. Adult patients have 
also reported feeling like they are posing a burden on their peers to meet their dietary needs when 
planning social events71. For adults specifically, it has also been reported that it is even more 
difficult to return to dietary management following a lapse in adherence. This may be due to a 
combination of the unpleasant taste of medical foods for PKU compared to foods containing high 
levels of natural protein and the symptoms of PKU associated with an increase in phe levels that 
make it more difficult to plan ahead and stick to a diet, such as a “mental fog” or difficulty 
planning71. 
2.3.4 Health-Related Quality of Life in PKU 
Health-related quality of life is a complex concept. It can be defined as a patient’s 
perspective on the impact their health has on their physical, emotional, social, and psychological 
well-being72. People who have PKU have reported feeling they are not reaching their full potential 
in work and in social relationships. They have also struggled with feelings of isolation due to 
stigma surrounding PKU or feeling that they could not explain their PKU to others in a way that 
would be understood71. While these statements were not explicitly tied to a decrease in quality of 
life, self-esteem and social relationships are key parts of quality of life, along with the 
neuropsychological impact of PKU. 
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There is evidence to suggest that people who have PKU experience an overall quality of 
life comparable to people in the general population23,24,73,74. However, some studies have found 
that quality of life is only comparable between people who have PKU and the general population 
for certain age groups. Huijbregts et al. found a significant difference in adults but not children or 
adolescents21, while Cotugno et al. found a significant difference in children and adolescents but 
not adults72. These two studies used different questionnaires to assess quality of life, neither of 
which was specific to PKU, and had different cut offs for when they used adult versus child 
questionnaires, with Huijbregts et al. using 16 as the minimum age for the adult questionnaires and 
Cotugno et al. using 18. They were also conducted in different parts of Europe (the Netherlands 
and Spain, respectively)21,72, which may also have played a role in their differing results. 
2.3.5 Management with Sapropterin  
Tetrahydrobiopterin (BH4), a cofactor of PAH, (and its synthetic form, sapropterin 
dihydrochloride) has been shown to be useful in managing mild cases of PKU, helping these 
patients have fewer, if any, dietary restrictions6,18,19. Sapropterin has been approved for use in 
people who have mild PKU in the United States since 200818. This treatment works by using 
sapropterin’s ability to promote PAH activity by stabilizing the enzyme and preventing it from 
being degraded prematurely36. A few studies have also shown a small proportion of patients who 
have classical PKU to benefit from sapropterin6,18. Sapropterin responsiveness is closely related to 
genotype. Quirk et al. found that the majority of patients who experience a definitive response to 
sapropterin had at least one, if not both, of their PAH mutations known to be mild or moderate in 
severity, while non-responders were more likely to have two severe mutations. There is also an 
intermediate group – provisional responders. These individuals show an initial decrease in phe 
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following initiation of sapropterin therapy, but cannot maintain phe levels of less than 360 μmol/L 
after increasing dietary phe intake75. However, genotype is not always predictive of 
responsiveness. The same study by Quirk et al. found that the majority of provisional sapropterin 
responders had two severe PAH mutations, suggesting that they were more likely non-responders. 
They also reported multiple instances where two patients who have the same genotype had 
different responses to sapropterin, with one being a provisional responder and the other being a 
non-responder75. 
In order to determine if a patient will be a responder to sapropterin, typically their genotype 
is first assessed to see if they have a mutation associated with mild or moderate reduction in PAH 
activity, allowing for residual PAH activity needed for sapropterin to be beneficial36. A trial of 
sapropterin may be considered for all patients, except those with two null PAH mutations15. When 
a potentially responsive genotype is established and sapropterin is administered, regular blood phe 
monitoring must then occur to determine if there has been a decrease in the patient’s phe levels. 
This monitoring often involves comparing the baseline phe level to phe levels at 24 hours, 1 week, 
and 2 weeks after initiating the sapropterin trial, but may continue to 3 or 4 weeks in some cases 
to capture a delayed response to sapropterin15. Typically, a patient will be considered a saptropterin 
responder if they have a 30% or greater decrease in their phe levels over this time, as long as their 
diet has remained stable or even increased in protein content during the trial15,36. Continued use of 
sapropterin can also be useful for patients who do not experience a decrease in phe levels, but do 
experience an increase in phe tolerance during the trial. While patients are typically told to 
maintain constant protein intake during the sapropterin trial, systematically adding protein to a 
patient’s diet during a sapropterin trial may be necessary for patients who have milder or better 
controlled PKU in order to see a substantial response15. 
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2.3.5.1 Effect of Sapropterin on Quality of Life 
There have been mixed findings on whether treatment with sapropterin leads to an 
improvement in quality of life. Studies that found improvement in quality of life typically only 
saw improvements in specific domains of quality of life compared to an overall improvement. 
Douglas et al. found that treatment with sapropterin, regardless of level of response, did 
significantly improve quality of life specific to the impact of PKU, but did not improve other areas 
of quality of life defined in their study (PKU-related life worries, satisfaction with life and medical 
managment, support from social network and medical community, and general well-being). They 
also noted significant increases in satisfaction only for definitive responders and in total quality of 
life score for both definitive and provisional responders, but not for non-responders20. Huijbregts 
et al. reported no significant differences in overall quality of life, but did find improvements in 
quality of life for adults taking sapropterin in the domains of pain, happiness, anger, and social 
functioning. They reported no similar improvements in children or adolescents21. Conversely, 
multiple studies have found no improvement in quality of life in any domain11,22. However, two 
studies reported participants who mentioned anecdotally that they enjoyed the increased dietary 
freedom provided by taking sapropterin, as well as the savings that came with a reduced need to 
purchase medical foods22,24.  
These discrepant findings have been explained in part by the fact that the questionnaires 
used in many of these studies were not disease-specific, suggesting that a questionnaire specific to 
PKU, or at least a chronic condition involving dietary restriction in general, would have been more 
informative21–24. This is especially relevant as Douglas et al., the study reporting the most 
significant improvements in quality of life, did use a questionnaire designed specifically for 
individuals who have PKU20. Further, the one significant improvement in quality of life seen by 
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Ziesch et al. was in patients who ultimately were not sapropterin responders, but who were on a 
less restricted diet for three months while determining their response status22. Although this was a 
temporary improvement that ended following a return to restricted diet after three months, this 
difference may be explained by non-responders tending to have lower PAH activity, and therefore 
lower phe tolerance and more restrictive diets, compared to responders33. The higher baseline phe 
tolerance of responders, and its associated less restrictive diet, may have limited the influence of 
initiating sapropterin on quality of life. This suggests that people who have classical PKU would 
have a higher chance of an improved quality of life with a less restricted diet, where such a benefit 
was not seen in patients who have milder forms of PKU20,73. This may be relevant as changes in 
quality of life are explored for newer therapies, such as pegvaliase, that are efficacious for patients 
who have classic PKU. 
A significant proportion of patients taking sapropterin eventually discontinued it. Insurance 
concerns, difficulty taking the required number of sapropterin tablets, undesirable side effects, and 
the treatment not working as well as expected were all reported reasons for discontinuation. While 
patients who discontinued sapropterin were more likely to have been less responsive to the drug, 
which is consistent with the complaint that it did not work as well as expected, the distribution of 
side effects was equivalent in patients who discontinued sapropterin and patients who chose to 
continue it. On the other hand, patients who chose to continue treatment with sapropterin focused 
on the dietary benefits of sapropterin, which allow for a lower phe level while maintaining a less 
restrictive diet involving fewer medical foods76. 
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2.4 Background on Palynziq/Pegvaliase 
Pegvaliase is an enzyme substitution therapy using recombinant phenylalanine ammonia 
lyase (PAL) from the bacterium Anabaena variabilis that is conjugated to polyethylene glycol 
(PEG), giving it it’s original name – PEG-PAL27,29. It is important to conjugate PAL to PEG in 
order to both mitigate an immune response against pegvaliase and maintain enzyme activity and 
stability because PAL is a bacteria-derived protein that does not naturally occur in humans27,77. 
PAL metabolizes phenylalanine into cinnamic acid and ammonia, which are both able to 
be metabolized safely by people who have PKU25. This allows PAL to be used to reduce phe levels 
to therapeutic range even in the absence of functional PAH26,27,29,31. PAL is an enzyme substitution 
therapy, as opposed to an enzyme replacement therapy, because it provides an alternate pathway 
for phe metabolism. Enzyme replacement therapies have been previously used in certain lysosomal 
storage disorders, another category of inborn errors of metabolism, and work by directly replacing 
the defective enzyme, instead of providing an alternative pathway78.  
Pegvaliase has been FDA-approved since 2018 for use in adults who have PKU and phe 
levels over 600μmol/L in the presence of past or current incomplete management with diet, 
sapropterin, or a combination of these management approaches25,28. It is not currently approved 
for use during pregnancy28. For this reason, some clinics may recommend women who are taking 
pegvaliase to continue incorporating specialized medical formula into their diet, but to a lesser 
degree than they might have needed prior to pegvaliase initiation. This is in order to ease the 
transition to dietary-based management during pregnancy (R. Mohring, personal communication, 
August 24, 2020).  
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2.4.1 Use of Pegvaliase 
Pegvaliase is self-administered by the patient via sub-cutaneous injection. Patients taking 
pegvaliase are informed about the potential adverse effects and administer pegvaliase in the 
presence of a trained observer, with both individuals being educated on how to use an epinephrine 
autoinjector in the event of a severe allergic reaction28,79. If support in the form of a trained 
observer is not available for a patient, then the risks and benefits of management with pegvaliase 
should be weighed28. All doses should be administered in a clinical setting until the patient and 
designated observer exhibit understanding of pegvaliase dosage and administration and ability to 
recognize signs of anaphylaxis, including what to do in the event of anaphylaxis. Use of 
antihistamines, specifically H1-receptor antagonists, prior to daily administration of pegvaliase is 
also recommended to help mitigate hypersensititivy reactions79. 
Initiation of pegvaliase therapy involves gradual titration of the drug up to 20mg/day over 
the course of 9 weeks or more to help minimize the risk of severe hypersensitivity reactions. 
Patients who experience adverse events may require a longer timeline due to the need to reduce 
pegvaliase dosage following a hypersensitivity reaction28,79. Complete discontinuation of 
pegvaliase following a hypersensitivity reaction is not recommended as this will delay 
desensitization to pegvaliase, and therefore put the patient at greater risk for future hypersensitivity 
reactions79. The dosage may then be titrated up to 40mg/day if the patient does not experience at 
least a 20 percent decrease in phe levels while on the 20mg/day dosing. When a patient does not 
experience this 20 percent decrease in phe levels within a year of pegvaliase initiation, treatment 
discontinuation is recommended. In contrast, if a patient experiences hypophenylalaninemia (phe 
levels under 30μmol/L) for three months or more, then dietary protein intake must be increased or 
pegvaliase dose decreased when dietary changes are not sufficient to raise phe levels28. Patients 
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who need to cease taking pegvaliase due to pregnancy or for other reasons may resume treatement 
with pegvaliase once they are able. However, they should start at a lower dose than they were 
taking when they stopped and gradually increase their dosage to prior levels as recommended by 
their clinic79. 
The goal of treatment with pegvaliase is to lower blood phe levels to 31-120μmol/L in the 
presence of a liberalized diet. Patients should also be educated on appropriate portion sizes and 
cooking methods for protein rich foods such at meat, eggs and fish, as they can be expected to 
have little prior experience with these foods if they were following the recommended low-protein 
diet. For some patients, it may also be important to address eating behaviors, as there is an 
increased risk of disordered eating patterns among people who have early-treated PKU due to the 
strict dietary management involved10,28,71. Although there is limited literature on this topic, it has 
been reported that women who have PKU scored higher on the oral control section of an 
assessment of eating attitudes and behaviors. This finding alone does not indicate a higher 
incidence of eating disorders, but does suggest a difference in the attitudes women who have PKU 
may have towards food.  Specifically, questions in this section assess self-control regarding food 
intake and whether a person feels pressured by others to gain weight, as may be the case for 
someone who is underweight due to an eating disorder, thereby possibly linking these higher scores 
to the recommended decreased protein intake of the typical PKU diet, which can require a 
significant level of self-control related to food80. 
2.4.2 Clinical Trials for Pegvaliase 
Clinical trials for pegvaliase were initiated by BioMarin in 200825. Approximately half of 
the 24 patients enrolled in a phase 2 clinical trial of pegvaliase were able to reach phe levels below 
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120μmol/L within 24 weeks without decreasing their dietary protein intake. The majority of the 
remaining half of the patients were able to achieve phe levels under 600μmol/L within 48 weeks, 
with many of these patients achieving levels below 120μmol/L by this time. The dosing regimen 
used in this clinical trial involved starting each patient at 2.5mg/week (0.5mg/day, 5 days a week) 
for the first 4 to 8 weeks. Their dose was then gradually increased over the course of at least 4 
weeks until their phe levels decreased to below 600μmol/L and remained beneath 600μmol/L for 
an additional 4 weeks without any additional dosing changes. The maximum dose used was 
375mg/week (75mg/day, 5 days a week)29. This was the first clinical trial of pegvaliase to show 
both decreased phe levels over time and an overall manageable safety profile, suggesting this was 
an appropriate dosing schedule27. The extension of this clinical trial reported that by week 48, 
57.4% of patients were able to reach phe levels below 600μmol/L, with 45.9% able to reach levels 
below 360μmol/L. Overall, by the end of the extension study, 82.5% of patients had experienced 
phe levels below 600μmol/L. This was accomplished while many of these individuals were on 
unrestricted diet27. 
The phase 3 randomized control trial for pegvaliase confirmed the efficacy and safety of 
pegvaliase in reducing blood phe levels. This 8-week trial recruited patients who were enrolled in 
previous clinical trials for pegvaliase and were therefore already taking pegvaliase. These patients 
were then randomized to continue taking their current dose of pegvaliase (either 20 or 40mg/day) 
or an equivalent dose of placebo. Patients who were switched to a placebo had significant increases 
in phe levels, while patients who continued on pegvaliase maintained their previously achieved 
decrease in phe levels. Patients in both groups were instructed not to change their dietary intake 
during the trial26. 
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The 20mg/day versus 40mg/day distinction for dosage was established during an earlier 
phase 3 clinical trial where pegvaliase-naïve patients were enrolled and randomized to either a 
20mg/day or 40mg/day dosage plan. These dosages were informed by the aforementioned phase 
2 studies and followed a similar titration plan – starting at 2.5mg/day and gradually increasing up 
to the dosage to which the person had been randomized. Overall, 78.3% of participants during 
phase 3 trials achieved a 20% or greater decrease in phe levels after taking pegvaliase for one year, 
while 60.7% reached levels below 360μmol/L and 51.2% reaching levels below 120μmol/L during 
this time31. 
2.4.2.1 Neuropsychiatric Improvements with Pegvaliase 
In a PKU mouse model, pegvaliase has been shown to reduce phe levels both in the blood 
and the brain. Along with this, tyrosine levels in the brain increased, even though blood tyrosine 
levels remained low. Accordingly, dopamine and serotonin levels increased as well. 
Norepinephrine levels were also noted to increase as phe levels decreased due to pegvaliase30. In 
humans, similar patterns were seen in patients who had a successful response to pegvaliase, 
including improvement of attention scores related to norepinephrine and dopamine levels being 
increased back to normal following a decrease in phe levels30. 
During the randomized clinical trial, patients who were switched to the placebo, and 
consequently experienced increased phe levels, showed worsening in multiple executive 
functioning domains (working memory, cognitive flexibility, and inhibitory control), as well as 
attention. In contrast, patients who continued on pegvaliase remained stable or improved in each 
of these abilities from week 1 to week 8 of the trial26. The earlier phase 3 clinical trial also showed 
that attention improved with lower phe levels induced by pegvaliase, demonstrating that patients 
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who experienced the greatest decrease in phe levels also had the most significant improvement on 
attention tests31.  
Significant improvements in mood were also reported during the earlier phase 3 trial, but 
not the randomized control trial. This may be because the initial phase 3 trial lasted for 2 years, 
while the randomized control trial only lasted for 8 weeks, and a longer period of time is likely 
required to see improvements in mood26,31. 
2.4.2.2 Immune Responses to Pegvaliase 
Enyzme replacement therapies and similar therapies that use an enzyme foreign to the 
patient’s body, such as enzyme substitution therapies like pegvalise, are known to induce an 
antibody response in some patients, which can lead to adverse reactions81. All patients in the phase 
2 clinical trial developed antibody responses against PAL and many developed a temporary 
response against PEG, both of which decreased overtime with the exception of PAL IgG, which 
remained consistently increased. No patients were positive for a drug-specific IgE, including 
patients who experienced anaphalaxis27,29,31,81,82. For PAL, over 75% of patients had PAL IgM at 
week 24 compared to under 50% at week 120. For PEG, PEG IgG and IgM were elevated in most 
patients at week 8, but had returned to normal by week 3627,31. Many participants had low-level 
titers for anti-PEG antibodies prior to starting pegvaliase due to the use of PEG in other 
medications and cosmetics, which did not seem to impact the safety of pegvaliase for these 
individuals82. 
The extent of a person’s immune reaction against pegvaliase is also important because it 
likely influences the effectiveness of the treatment. Phase 2 studies suggested that if there is a 
strong immune response, then the immune system will clear pegvaliase from the person’s system 
more rapidly, requiring a higher dosage29. This was further supported by phase 3 trial data showing 
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that patients who had lower antibody titers early in treatment with pegvaliase were more likely to 
have a greater and more rapid decrease in phe levels. However, even participants who had a strong 
immune reaction were shown to have a significant reduction in phe levels81. It was also noted in 
several of the clinical trials that adverse events, described below, were most common in the early 
months following initiation of pegvaliase when antibody levels were highest, especially anti-PEG 
antibodies28,29,31. This is not unexpected because PEG is on the surface of PAL, making it easier 
for anti-PEG antibodies to bind to pegvaliase and initiate an immune response compared to anti-
PAL antibodies82. However, presence or level of a specific antibody was not predictive of any 
particular adverse event31,81.  
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2.4.2.2.1 Safety Profile of Pegvaliase 
Anaphylaxis occurred in the clinical trials but was not common. It happened only in two 
patients out of the 80 who enrolled in phase 2 trials. Both of these patients had multiple events of 
anaphylaxis, with anaphylaxis occurring both during the initial 24 weeks of the trial and during 
long-term treatment 27,29. Other hypersensitivity adverse events were more common, occurring in 
most (91.2%), but not all patients in phase 2 trials. These reactions included rash, arthralgia (joint 
pain), urticaria (hives), pruritis (itching), and pyrexia (fever)27. Overall, during the first 24 weeks, 
the most common reactions were arthralgia and injection-site reactions. After the first 24 weeks, 
when many patients had reached their maintenance dose associated with decreased phe levels, the 
most common reaction was urticaria. In general, adverse events decreased in frequency over time 
once an effective dose for an individual had been established and their dosage was no longer being 
systematically increased27,29. Most adverse events were also mild or moderate in nature and did 
not lead to discontinuation or changes in dosing26,27,29,31.  
A similar adverse event profile was reported by phase 3 clincal trials26,31,81. Importantly, 
there were similar rates of adverse effects reported by both the placebo and pegvaliase groups 
during the randomized control trial26. This could not be investigated during the phase 2 trials as 
there were no control groups for comparison. 
2.4.3 Impact of Pegvaliase on Patients 
A survey distributed to people who have PKU by NPKUA in 2015 showed that over 90% 
of respondents stated it was important to find new, improved treatments for PKU. This was true 
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for patients both within the recommended phe range of 120 to 360μmol/L and patients above 
360μmol/L. Similarly, 90% of respondents, both with phe levels within and exceeding the 
recommended range, reported desiring a new treatment to help lower blood phe levels. Fifty-seven-
percent of respondents stated that they were content with their current treatment, but were hopeful 
for better treatments to be developed in the future, while 35% stated that they have difficulty with 
their current treatment60. Pegvaliase has the promise to begin to address these concerns for a 
substantial portion of people who have PKU, with the exception of those who have a preference 
for oral medications over injections60. 
A more recent study compared data on blood phe levels and natural protein intake from 
participants in the phase 2 and 3 pegvaliase clinical trials to those enrolled in a PKU patient 
registry. The study was designed to investigate the effectiveness of pegvaliase versus sapropterin 
plus diet versus diet alone management approaches in adults with PKU. They found that patients 
who were taking pegvaliase had both the lowest phe levels and highest natural protein intake on 
average, suggesting that pegvaliase is the most effective treatment for patients who have been 
previously unable to keep their phe levels below 600μmol/L83. This creates the potential for 
pegvalise to improve quality of life for people who have PKU on the basis of reducing 
neuropsychiatric and cognitive symptoms by lowering phe levels and allowing for liberalization 
of diet. 
These anticipated impacts on quality of life are highlighted by a study on patient 
perspectives of pegvaliase and how they weight the risks versus benefits of the treatment. Using a 
survey, this study was able to show that, on average, adults who have PKU and currently have a 
blood phe level of over 600μmol/L are willing to use pegvaliase as long as there is at least a 22.7 
to 34.4% chance of achieving phe levels below 600μmol/L. These patients were aware of the 
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potential adverse effects and the frequency of these events among patients enrolled in clincal trials. 
They were also aware that pegvaliase is administered via injection, which contributed to a sub-set 
of respondents (4 out of 45) being less willing to use pegvaliase. Notably, the percent of patients 
who reach and maintain phe levels below 600μmol/L by taking pegvaliase is much higher than 
34.4%, as discussed previously84. This is similar to the results of a survey distributed by the 
NPKUA, which showed that most respondents were willing to experience mild reactions such as 
injection site reactions or skin irritation, but less willing to risk severe reactions such as 
anaphylaxis60. As part of the risk-benefit survey, respondents also reported on the burdens created 
by managing and living with their PKU. The reported burdens impacted multiple areas of life, 
including social activities, cognitive ability, and overall lifestyle. These burdens possibly explain 
why many respondents were willing to try pegvaliase even if there was an over 70% chance that 
it would not reduce their phe levels below 600μmol/L84.  
A smaller study involving 26 patients in Germany who had phe levels above 600μmol/L 
reported that most of the patients (73%) refused treatment with pegvaliase due to fear of the 
adverse effects, administration via injection, or not feeling a need for additional treatment at this 
time; there was a 4-week gap between the initial appointment providing information on pegvaliase 
and the follow-up appointment where the patient was asked for a decision regarding pegvaliase, 
during which time several of the patients who refused pegvaliase were able to reduce their phe 
levels closer to or below 600μmol/L. These differences in patient preference may reflect the 
differences in guidelines in the United States compared to Europe. As Europe has a higher target 
phe level for adults (600μmol/L), patients in Europe may feel less pressured to achieve lower phe 
levels with new treatments like pegvaliase, compared to patients in the United States where the 
target phe level is lower85,86. 
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2.5 Future Directions for PKU Management: Gene Therapy 
Gene therapy is actively under investigation for PKU. It has typically targeted the liver, the 
site of PAH activity. As mentioned previously, PKU is inherited in an autosomal recessive pattern, 
with carriers having normal phe levels despite having decreased PAH activity. This will likely help 
with the gene therapy approach because it will only be necessary to restore PAH activity to the 
level of a healthy carrier, not 100% activity. In addition, mouse models have shown that having at 
least 10% of liver cells with functional PAH is sufficient to lower phe levels to normal range, even 
if this subset of cells are heterozygous for PAH mutations86.  
The initial approach to gene therapy for PKU in mouse models involved a recombinant 
retrovirus. This approach caused a strong immune response against the virus, necessitating a 
different approach, a recombinant adeno-associated virus. Multiple pharmaceutical companies 
have stated that they plan to conduct clinical trials for gene therapies that would use a viral vector 
to introduce functional PAH in liver cells. However, the benefits may only be temporary, especially 
in pediatric cases where liver cells are still rapidly dividing, because these approaches do not 
incorporate the vector carrying functional PAH into the cell’s genome86. 
Non-viral approaches, such as RNA, are also under investigation, along with gene editing 
using CRISPR/Cas986,87. While previous approaches with CRISPR/Cas9 have been prone to error 
and therefore not suitable for use in humans, a new method was recently developed that allows for 
precise editing of single base pairs. This newer method has since been tested in a mouse model 
and shows potential for use in future gene therapy. Such an approach would be expected to have a 
more permanent impact than one using viral vectors, as this would permanently repair the mutation 
within cells, allowing it to be passed on when the cell divides86,88. One study on gene editing as a 
treatment for PKU in mice used a recombinant adneo-associated virus vector to deliver the Cas9 
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enzyme, guide RNA, and repair template to liver cells of the mice in order to correct a missense 
mutation in Pah for which the mice were homozygous. While the rate of successful gene editing 
by homology directed repair was only 13.06%, they did report a decrease in blood phe levels and 
a complete reversal of associated physical and behavioral symptoms. This improvement persisted 
for the remaining lifetime of the mice that had successful gene editing. A separate study on gene 
editing in Pah-deficient mice used base editors that do not require homology directed repair to edit 
the gene. This study reported up to 25.1% correction of Pah89. However, as the mice in each of 
these studies all had the same mutation, the same guide RNAs were used, which would not be the 
case in humans considering there are over 1,000 known PAH mutations, further complicating the 
translation of this approach to humans88,89. 
It is also important to consider the high costs that will be associated with gene therapies, if 
they are successfully developed. This must then be weighed against potential benefits, such as 
requiring fewer injections – possibly only one in a lifetime – compared to pegvaliase which 
requires daily injections87,88. There is an apparent interest in a one-time management approach, 
like gene therapy, among people who have PKU. A survey distributed to people who have PKU 
by the National PKU Alliance found that 85% of respondents would be interested in a single-dose 
gene therapy for PKU60. Overall, future comparisons will be possible between the ability of 
pegvaliase and of gene therapy to impact quality of life for people who have PKU due to their 





Phenylketonuria (PKU) is one of the most common inherited metabolic disorders, with an 
estimated incidence of 1 in 15,0001. It was the first condition to be included on newborn screening, 
following development of an assay by Guthrie and Susi in 1963 that could be conducted on a dried 
blood spot2. PKU is part of a group of conditions titled hyperphenylalaninemia, all of which are 
characterized by elevated levels of the essential amino acid phenylalanine (phe). Severity of 
hyperphenylalaninemia in the context of PKU can be separated into three categories: classical 
PKU (phe concentrations greater than 1,200 μmol/L), mild PKU (phe concentrations between 600 
to 1,200 μmol/L) and non-PKU hyperphenylalaninemia (phe concentrations between 120 to 600 
μmol/L)1. PKU is inherited in an autosomal recessive pattern due to pathogenic variants in PAH, 
which encodes phenylalanine hydroxylase (PAH) – the enzyme responsible for converting phe to 
tyrosine in humans1. Over 1,100 different pathogenic variants have been reported to date3, with 
some correlation between variant type and severity of PAH deficiency4–6. 
When untreated, classic PKU causes a range of symptoms including intellectual 
disabilities, seizures, and impaired motor skills7,8. With the advent of newborn screening, early 
treatment can be initiated to prevent or mitigate these symptoms, however certain symptoms such 
as anxiety and depression, attention and executive functioning deficits, and lower IQ (but not 
usually to the extent of intellectual disability) may continue even with appropriate treatment9–14. 
Treatment for PKU originally relied solely on dietary restriction of protein, and therefore of phe, 
supplemented by medical formulas that contain all amino acids except phe, and other essential 
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nutrients15. These dietary restrictions were once only routinely followed during childhood16,17, but 
treatment for life has been the standard recommendation in the United States since 200016. 
In 2008 an oral therapy, sapropterin dihydrochloride (Kuvan, BioMarin Pharmaceuticals), 
a synthetic form of tetrahydrobiopterin (BH4) – a cofactor of PAH, was approved by the FDA18. 
This therapy successfully lowers phe levels in many people who have mild PKU but typically does 
not provide a clinical benefit to people who have more severe, classical PKU6,18,19. Several studies 
have been conducted to measure the impact this therapy had on the quality of life of patients who 
responded to the medication. These studies largely found that there was not a significant increase 
in quality of life subsequent to treatment with sapropterin and the associated relaxation of dietary 
restrictions, with only one study showing an improvement in multiple domains of quality of 
life11,20–22. Notably, the study that showed improvements in quality of life was the only one to use 
a quality of life questionnaire specific to PKU;  this questionnaire was adapted for use in the current 
study. It has also been postulated that improvements in quality of life due to dietary relaxation for 
some patients following treatment with sapropterin may be limited, since these patients typically 
have a less stringent diet at baseline compared with people who have more severe or classic PKU21–
24. It therefore can be postulated that patients who have more severe PKU may experience a greater 
improvement in quality of life following an effective treatment that allows for dietary relaxation. 
In 2018, a treatment received FDA approval for adults who have classical PKU. Pegvaliase 
(Palynziq, BioMarin Pharmaceuticals) is an injectable enzyme substitution therapy using 
recombinant phenylalanine ammonia lyase, a bacteria-derived enzyme that converts phe to 
cinnamic acid and ammonia25. It has been shown to be effective in lowering phe levels for adult 
patients with phe levels over 600μmol/L25–29. As this is a more recently approved therapy for PKU, 
many studies have been published on the effectiveness and safety of pegvaliase from a clinical 
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standpoint, including improvement of neuropsychiatric symptoms26,30,31. However, no studies on 
impact of pegvaliase on quality of life for individuals taking it have been published to date. The 
goal of this study was use an online questionnaire to investigate quality of life impacts, focusing 
specifically on 1) assessing psychosocial and neuropsychiatric impacts of pegvaliase, 2) 
determining how pegvaliase has changed the dietary decision making of patients using it and how 
this could translate to an impact on quality of life, and 3) identifying residual resource and support 
needs for patients taking pegvaliase. By learning more about how a treatment, like pegvaliase, can 
impact a patient’s life beyond lowering their phe levels, providers can continue to improve overall 
care for these individuals. These continued improvements may include providing anticipatory 
guidance on the benefits and limtations of such treatments and linking patients to additional 
resources and supports as needed. 
3.2 Methods 
3.2.1 Study Participants 
The target population for this study was adults 18 and older who have PKU, including 
individuals who are currently taking pegvaliase, have never taken pegvaliase, and have taken 
pegvaliase previously but are no longer taking it. Children were excluded from this study as 
pegvaliase is currently only FDA approved for use in adults. This study and its corresponding 
survey have been approved by the University of Pittsburgh (Appendix A) and National PKU 
Alliance (NPKUA) IRBs. 
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3.2.2 Survey Development 
The survey constructed for this study (Appendix B) included the following topics: 1) 
introductory paragraph, 2) eligibility questions and demographics, including phe levels, 
management of PKU and employment and/or student status, 3) general quality of life, 4) quality 
of life in relation to management of PKU, 5) quality of life in relation to impact of PKU on daily 
life, 6) worries surrounding PKU, 7) assessment of current resources and supports and residual 
needs, 8) cognitive symptoms, and 9) depressive symptoms. The quality of life portions of the 
survey were based in large part on a previously developed survey of PKU-specific impacts on 
quality of life, used with permission from Dr. Rani Singh, the corresponding author for the study 
which originally constructed the survey (Appendix C.1). Additional questions were added to assess 
residual resource needs, and certain questions determined to be redundant were removed to help 
keep the survey at a reasonable length. Internal consistency was calculated with Cronbach’s alpha 
values for each construct in the present survey to assess whether items within the construct were 
correlated with each other, as intended. This was done to ensure that this addition and removal of 
questions did not compromise the survey, although they were previously calculated for each 
construct in the questionnaire on which the quality of life portion of the present survey was based. 
Questions assessing cognitive and depressive symptoms were taken verbatim from Neuro-
QOL short forms (Neuro-QOL Item Bank v2.0 – Cognition Functions – Short Form, Neuro-QOL 
Item Bank v1.0 -Depression – Short Form) available from the NIH Toolbox HealthMeasures and 
were adapted for use in an online survey with permission from the HealthMeasures staff (Appendix 
C.2). Overall, the process of determining which questions to use, add, or exclude was conducted 
with the input of multiple people, including providers in the PKU Clinic and a neuropsychologist 
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at UPMC Children’s Hospital of Pittsburgh and an individual who has PKU and is who is 
pegvaliase. 
The survey implemented skip logic at multiple points to ensure that participants were only 
asked relevant questions. Examples of this included only asking follow-up questions about 
pegvaliase for individuals who reported using pegvaliase either currently or previously and only 
inquiring about the impact of PKU on a person’s work or schooling if they reported being 
employed or having student status. The survey was accessible through an anonymous Qualtrics 
link, in compliance with the University of Pittsburgh’s University Data Security standards. 
Written informed consent was deemed unnecessary due to the nature of the study as an 
anonymous  online survey, and an introductory paragraph detailing the study was provided to 
potential participants upon accessing the survey link. This included information on the purpose of 
the study, eligibility, potential benefits and risks, and contact information for the primary 
investigators (Appendix B).  
 
3.2.3 Survey Recruitment and Distribution 
Recruitment for this study was conducted in two ways, 1) through coordination with 
NPKUA on emailing an informational paragraph on the study, including a link to the survey, to 
their patient registry twice – once in December to initiate data collection and once in February as 
a final reminder to complete the survey, and 2) through the PKU clinic at UPMC Children’s 
Hospital of Pittsburgh, with help from the clinic’s nurse. Both of these methods distributed the 
same informational paragraph (Appendix D). Recruitment at UPMC Children’s Hospital of 
Pittsburgh did not begin until after the survey had been distributed to the NPKUA patient registry. 
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NPKUA further helped with recruitment by including a section on the study in their January 
newsletter which was similar to the original informational email.  Recruitment from both methods 
lasted from December 2020 through February 2021. The informational paragraph used by both 
recruitment sites consisted of a condensed version of the introductory script of the survey 
(Appendix E).  
3.2.4 Data Analysis 
The anonymous responses to the Neuro-QOL short-forms on cognition and depression 
were transferred to a Microsoft Excel spreadsheet where they were scored based on the 
standardized scoring system previously available from the NIH Toolbox Health Measures. For the 
cognition short-form, responses scoring 16 or less (2 SD below the mean) were identified to allow 
two separate data analyses – one including these respondents’ answers and one excluding them. 
Demographics (degree of phe control, management approaches, and student/employment status) 
were noted for these respondents as well. This was done in order to determine if there were any 
respondents who may not have been able to fully understand the questions asked in the survey by 
assessing different response patterns, and the impact this may have had on the data. These 
individuals were included in some parts of the analysis in order to better understand how PKU can 
impact cognition in adults, even ones who are using various management approaches. 
Responses to quality of life questions were also scored in accordance with the scoring 
method for the questionnaire on which the present survey was based, with each response being 
assigned a value of 1 to 5 and higher scores indicating a lower quality of life. In cases where a 
question was not applicable to a respondent or the respondent chose to skip a question, leaving the 
question unanswered, the missing responses were imputed based on present responses. Scoring 
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protocols for the quality of life questions, by sub-section, and the Neuro-QOL Short forms are 
available in Appendix E.  
These scores were then compared between respondents who reported taking pegvaliase and 
those who reported not taking pegvaliase, as well as between respondents who reported their most 
recent phe level being below 600μmol/L and those who reported their most recent level as 
600μmol/L or higher. These comparisons were made using a Wilcoxon rank-sum test. Specific 
questions from the quality of life assessment were analyzed using a Fisher’s exact test in order to 
further investigate the relationship between elevated phe levels and the emotional costs of dietary 
management and guilt related to phe levels,  to enable comparison to previously published 
literature on this topic90–92. Comparisions regarding the distribution of reported phe levels, reported 
frequency of phe measurements, and presence of residual resources needs, each related to 
pegvaliase use,  as well as comparisions of degree of dietary change by reported phe level and 
length of time taking pegvaliase, were done using a Fisher’s exact test. The statistical software 
used was StataSE, version 16.1.872. 
For the three open-ended questions (Table 1), thematic analysis was conducted as described 
by Braun and Clark (2006)93. The codes and themes and overarching patterns were first identified 
by the primary investigator, then reviewed by two additional study team members. Modifications 




Table 1 Open-Ended Questions Included in Survey 
Question was visible to Question Content 
Only respondents taking 
pegvaliase 
What caused you to make this change in your diet (or to not 
make a change) [following initiation of pegvaliase]?  
All respondents 
Are there any other areas of your life where you wish you 
had more support? 
All respondents who reported 
they need additional resources 
Please describe these additional resources you need. 
 
3.3 Results 
3.3.1 Demographics  
Forty-three eligible individuals began the survey, with 36 individuals completing the entire 
survey. Ten of the 43 (23.2%) respondents reported being a current student and 31 (72.1%) 
reported being currently employed, with 4 (0.9%) individuals being both a student and employed. 
Of these, 13 reported taking pegvaliase currently and one reported taking pegvaliase previously. 
All 14 of these individuals completed the survey in its entirety. Details about the number of 
respondents taking and not pegvaliase relative to the number of participants with phe levels at or 
below 600μmol/L appear in Table 2. Although a higher percent of respondents who were taking 
pegvaliase had phe levels below 600μmol/L compared to the group of respondents who were not 
taking pegvaliase, this did not reach statistical significance (p-value: 0.49) 
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Table 2 Number of respondents by pegvaliase status and phe level range 
 Taking pegvaliase (%) Not taking pegvaliase (%) Total 
Phe levels at/below 600μmol/L 10 (77%) 18 (60%) 28 
Phe levels above 600μmol/L 3 (23%) 12 (40%) 15 
Total 13 (100%) 30 (100%) 43 
 
With regards to other management approaches, 17 respondents reported taking sapropterin 
and 35 reported using dietary management. A more detailed combination of management 
approaches, including combinatory approaches, is available in Table 3. 
 
Table 3 Number of respondents reporting utilization of different management approaches, including those 
involving multiple different types of management 
Management Approach(es) Number of Respondents Reporting Use 
Pegvaliase only* 4 
Pegvaliase + Sapropterin 1 
Pegvaliase + Diet 3 
Pegvaliase + Sapropterin + Diet 4 
Sapropterin only 2 
Sapropterin + Diet 10 
Diet only 18 
*One respondent who reported taking pegvaliase did not answer the question regarding additional management 
approaches and is not included in this table. 
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Reported frequency of phe measurements ranged from once a week to less than once a 
month. Phe measurements were taken significantly more frequently in respondents who were 
taking pegvaliase than respondents who were not (p-value: 0.02), and both of the respondents who 
reported measuring their phe levels weekly were taking pegvaliase (Figure 1). One of these 
respondents had been taking pegvaliase for less than six months and the other had been taking it 
for a year or more. 
 
 
Figure 1 Number of respondents measuring their phe levels at specified frequencies, by pevaliase status 
 
Phe levels were also lower on average among respondents taking pegvaliase than 
participants who were not, and all three respondents who reported phe levels below 120μmol/L, 




Figure 2 Blood phe levels, by pegvaliase status 
3.3.2 General Impact of Pegvaliase  
Of the participants who reported taking pegvaliase, four had been taking it for less than six 
months, two had been taking it for six to nine months, and seven had been taking it for a year or 
more. All of the respondents who reported that their diet had changed appreciably had been taking 
pegvaliase for at least a year, although there was variation in the degree of dietary protein change 
among respondents who reported taking pegvaliase for this length of time (Table 4). There was no 
50 
significant difference when comparing reported degree of dietary change by length of time taking 
pegvaliase (p-value: 0.29) or recent reported phe levels (p-value: 0.15). 
 
Table 4 Degree of dietary protein change since initiation of pegvaliase, by length of time taking pegvaliase 
 No change in diet Diet changed a little Appreciable change 
<6 months 2 2 0 
6 months to <9 months 2 0 0 
1 year or more 2 1 4 
TOTAL 6 3 4 
*No respondents reported taking pegvaliase for 9 months to less than a year. 
 
Reasons for change in dietary protein intake, or lack thereof, were elucidated with the open-
ended question, “What caused you to make this change in your diet (or to not make a change)?” 
Seven of the 13 respondents taking pegvaliase answered this question. One respondent may have 
misunderstood the question and answered “My levels started getting harder to manage in my 
teens,” which is not directly applicable to the question asked. Otherwise, each respondent 
mentioned either the time delay associated with lowered phe levels after starting pegvaliase (n=1), 
positive changes related to pegvaliase, including decreased phe levels, increased protein intake, 
and improvements in day to day life (n=4), or both a time delay and positive changes (n=1). Time 
delays were cited as a reason for why a respondent’s diet had not yet changed since initiation of 
pegvaliase, and were potentially a source of frustration for the two respondents who were still 
waiting for the potential positive effects of pegvaliase to be realized. Notably, the respondent who 
mentioned both future positive impacts of pegvaliase, and the expected time needed for those to 
take effect, placed particular emphasis on expectations for cognitive improvements, saying: 
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I have a greater desire to feel more normal. Mostly when it comes to 
cognition and brain clarity. I need to be able to function better, especially with 
my memory. The food option changes (once they come) will just be an added 
bonus. I'm more concerned with my mental clarity and how that will translate 
to my mental capabilities when I'm in my 80s and on… 
Another respondent shared his/her positive experiences in relation to participation in clinical trials 
and beyond, and positive feelings towards the process and resulting outcome: 
Palynziq. I went from 5 grams of protein a day to 55. I have been on it 
for over 4 years as I was a patient in the FDA trial and I do not regret that 
decision at all. 
Taking pegvaliase came with some degree of side effects for the majority of respondents 
(85.7%), with six of these reporting that these side effects did not impact their quality of life and 
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the other six reporting that their side effects impacted their quality of life. No respondents reported 
that the side effects of pegvaliase impacted their life significantly (Table 5). 
 
Table 5 Impact of pegvaliase side effects on quality of life, by length of time a respondent has been taking 
pegvaliase 
 IMPACT OF SIDE EFFECTS 
TIME ON 
PEGVALIASE 




quality of life 
Not impacting 
quality of life 
<6 months 3 1 0 
6 months to <9 months 0 2 0 
1 year or more 2 3 2 




3.3.3 Quality of Life  
 
Figure 3 Self-reported overall health: All respondents (top), by pegvaliase status (bottom) 
 
Overall, the majority of respondents reported they felt their health is good or excellent 
compared to other people their age, with only four (9.3%) of all respondents stating they felt 
their health was poor compared to others (Figure 3). Each of the individuals who selected “Poor” 
also reported not taking pegvaliase, and three of the four had phe levels above 600μmol/L 
The scores for the quality of life portions of the survey are summarized in Table 6, sorted 
by sub-section and sub-group within the study sample. When comparing respondents taking 
pegvaliase to those who do not, a significant difference was found for satisfaction with 
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management (p=0.03). This was the only significant difference identified when comparing these 
two groups but general satisfaction with life approached statistical significance (p=0.05). A 
number of differences were noted when comparing respondents who had phe levels below 
600μmol/L to those who had phe levels of 600μmol/L or higher. These differences were seen in 
general life satisfaction (p=0.02), satisfaction with management (p=0.01), impact of PKU 
(p=0.04) and overall quality of life score (p=0.02). No significant differences in PKU-related 
worries or satisfaction with supports were seen when comparing by pegvaliase status or phe 
level. Across all sub-sections, regardless of whether a statistically significant difference was 
seen, respondents who had lower phe levels had better scores on average than those who had 
higher levels and respondents who were taking pegvaliase had better scores on average than 
those who were not taking it. This pattern was also present for total scores.   
Internal consistency of each sub-section, as calculated with Cronbach’s alpha were:  0.85 
for general satisfaction with life (11 questions), 0.88 for satisfaction with management (14 
questions), 0.88 for impact of PKU (15 questions), 0.91 for PKU-related worries (11 questions), 
and 0.78 for satisfaction with support (four questions).  These scores indicate acceptable to 
excellent internal consistency among the questions in each of the sub-sections, making it 
appropriate to analyze differences between the average scores of different groups on these sub-
sections, as was done for the above analysis.
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Table 6 Quality of life section(s) scores and comparisons by pegvaliase status and phe level 
 
Sub-Group n Mean  SD Min-Max (Range) p-value 
General Life Satisfaction 
Possible scores: 11-55 (median: 33) 
Pegvaliase 13 22.17  4.95  13.75-30 (16.25) 
0.05 
No Pegvaliase 30 28.11  9.37 13-46.75 (33.75) 
Phe <600μmol/L 28 23.9 7.19 13-37.125 (24.125) 
0.02* 
Phe ≥600μmol/L 15 30.8  9.64 16-46.75 (30.75) 
Satisfaction with Management 
Possible scores: 14-70 (median: 42) 
Pegvaliase 13 33.15  13.38 14-60 (46) 
0.03* 
No Pegvaliase 30 41.27  10.3 25-63 (38) 
Phe <600μmol/L 28 35.61  11.23 14-55 (41) 
0.01** 
Phe ≥600μmol/L 15 44.8  10.66 25-63 (38) 
Impact of PKU 
Possible scores: 15-75 (median: 45) 
Pegvaliase 13 37.92  9.51 22-54 (32) 
0.38 
No Pegvaliase 29 41.65  11.33 23-62 (39) 
Phe <600μmol/L 27 37.95  10.97 22-62 (40) 
0.04* 
Phe ≥600μmol/L 15 45.07  9.22 31-60 (29) 
Lower score =  higher quality of life (for any sub-score and overall score), *p-value less than 0.05, **p-value less than or equal to 0.01 
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 Table 6 Quality of life section(s) scores and comparisons by pegvaliase status and phe level 
PKU-Related Worries 
Possible scores: 11-55 (median: 33) 
Pegvaliase 13 29.27  10.84 14-47.3 (33.3) 
0.66 
No Pegvaliase 28 30.75  12.33 11-52.8 (41.8) 
Phe <600μmol/L 27 28.41  11.32 11-49.5 (38.5) 
0.16 
Phe ≥600μmol/L 14 33.88  12.17 15.4-52.8 (37.4) 
Satisfaction with Support 
Possible scores: 4-20 (median: 12) 
Pegvaliase 13 7.31  2.86 4-12 (8) 
0.32 
No Pegvaliase 28 8.68  3.88 4-17 (13) 
Phe <600μmol/L 27 7.81  3.39 4-15 (11) 
0.36 
Phe ≥600μmol/L 14 9.07  4.01 4-17 (13) 
TOTAL 
Possible scores: 55-275 (median: 165) 
Pegvaliase 13 129.82  34.02 72.86-189.3 (116.44) 
0.25 
No Pegvaliase 28 139.2  41.09 84.3-223.5 (139.2) 
Phe <600μmol/L 27 133.117  37.77 72.86-209.5 (136.64) 
0.02* 
Phe ≥600μmol/L 14 162.69 +36.95 118.9-223.5 (104.6) 
Lower score =  higher quality of life (for any sub-score and overall score), *p-value less than 0.05, **p-value less than or equal to 0.01 
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Analysis by phe level of responses to the questions that were specifically analyzed due to 
their indirect relationship to the emootional costs of dietary restrictions and the potential for guilt 
surrounding elevated phe levels is included in Table 7.  There was a clear, statistical difference in 
satisfaction with phe levels (p = 0.01), as people who reported lower phe levels reported higher 
satisfaction with their levels. For the possible emotional costs of dietary restriction, the only 
significant difference was found in the impact of PKU on leisure activities, where people who 
reported lower phe levels reported less of an impact (p = 0.01). In contrast, there was not a 
significant difference by phe level for the impact of PKU on going out to eat (p = 0.22). 
However, only people who reported phe levels under 120 μmol/L consistently reported having 
no negative impacts for both the general-leisure and going-out-to-eat questions. There was no 
significant difference found regarding perceived restrictiveness of diet in either question 




Table 7 Analysis of responses to specific QOL questions related to the potential for guilt associated with 
elevated phe levels and the emotional costs that can be associated with a strict low-phe diet 
Responses were grouped by reported phe level allowing comparisions to be made between the group of people 
who reported phe levels ≥600μmol/L and the group who reported phe levels <600μmol/L. 




How satisfied are you with your current phe level? 0.01** 
How satisfied are you with the flexibility you have 
in your diet? 
0.08 
Impact of PKU 
(n = 42) 
How often do you feel restricted by your diet? 0.15 
How often do you think that your PKU interrupts 
your leisure-time activities? 
0.01** 
How often do you find that your PKU prevents you 
from going out to eat with your friends? 
0.22 
*p-value less than or equal to 0.01 
3.3.3.1 Resources and Supports, Present Use and Residual Need 
Satisfaction with support from family and friends, as well as doctors and dieticians, was 
assessed as part of the quality of life portion of the survey, summarized in Table 6. Additional 
supports were identified by 16 repondents. Identified support persons included mental health 
professionals and significant others, with pets being mentioned, as well. Support organizations, 
such as churches or university-based disability services were also mentioned. One respondent 
reported that they do not receive any support. The types of support provided are shown in Figure 
4. Two respondents provided more detailed information about the types of support received: 1) 
“Housing accommodations to prevent my food needs from interfering with my school schedule” 
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in relation to support from University-based disability services and 2) “[My boyfriend] helps me 
make low protein meals often.” 
 
Figure 4 Number of respondents reporting types of support provided by support persons and organizations 
*Total exceeds the number of participants as respondents were able to select multiple options. 
 
Eighteen respondents answered the open-ended question, “Are there any other areas of 
your life where you wish you had more support?”  Four stated “No” or “None,” including one 
respondent taking pegvaliase. Of the other fourteen responses which indicated a residual support 
need, only one of these was from a respondent taking pegvaliase. This individual focused on 
support from insurance companies and the government. Three respondents who were not taking 
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pegvaliase also reported needing financial supports or better support from insurance, although 
supports related to social interactions and health care were more common.  
Responses regarding social support ranged from general statements of isolation such as  “I 
wish I had more people in my life with PKU” and the “social effects of lack of friends” to more 
complex social situations. As one respondent stated: 
I wish I had more food support, as in I wish my significant other/s 
didn't eat things I can't eat around them because that is when I break my diet 
(even though its an unrealistic expectation). 
The difficulty of navigating such social situations was also mentioned by another respondent in 
the later open-ended question regarding resource needs. 
From a health care perspective, several of the responses revolved around support in 
managing PKU or accessing different management approaches such as sapropterin. One 
respondent also mentioned a need for support regarding “weight management/weight loss with 
PKU.” 
Other areas of residual support needs included support in employment and education, 
including identification of unspecified educational leaders by one respondent.  
There were a variety of utilized resources reported, with the most common being: NPKUA 
and online support groups. A full summary is included in Figure 5. For the two respondents who 
selected “Other”, one reported using their state’s PKU organization and the other reported using 




Figure 5 Number of respondents utilizing various resources (n=38); The total reflected in this figure exceed 
the number of respondents because respondents were able to select more than one option. 
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There was a trend among respondents who were taking pegvaliase toward not reporting 
additional unmet resource needs, although there were a few respondents who were taking 
pegvaliase who indicated they were missing key resources (Figure 6). However, this trend did not 
reach statistical significance (p-value: 0.19). 
  
 
Figure 6 Number of respondents reporting residual resource needs, by pegvaliase status (n=41) 
 
Of the 25 respondents who selected “Yes” on the multiple choice question – “Are there 
any other areas of your life where you wish you had more support?” (Answer Options: Yes/No), 
15 provided additional details as to what kinds of additional supports they desire. Two of these 15 
respondents were taking pegvaliase, and both reported residual financial support needs alone. 
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Among respondents not taking pegvaliase, financial resources, including “tools to make financial 
management easier with PKU,” were mentioned as well, with one respondent specifically 
mentioning the financial burden of paying for certain resources like Howmuchphe. This 
respondent stated: 
Howmuchphe is 45 dollars a year which is expensive, I'm a student and 
don't work and that’s a lot of money to spend on an app. 
The other primary concerns related to resources for these individuals included health care, 
encompassing access to doctors and management approaches like sapropterin and pegvaliase 
(including one respondent based in Canada who was waiting for pegvaliase to become available 
there) and adult-specific resources. These adult-specific resources included both adult-focused 
PKU clinics and social resources. As one respondent mentioned: 
I wish I knew about more support groups for adults with PKU and 
especially women of childbearing age, I have no idea who to talk to about 
personal maternal PKU experiences. 
Another respondent mentioned: 
Age specific peer support. Everyone else my age already has kids and 
support is always geared toward kids or people who have kids. 
Three respondents were also seeking additional information as a resource. Two of these 
respondents were seeking information for themselves in the form of either “information about the 
simplified diet” or “peer reviewed journal articles; more scientific knowledge of PKU at the 
biochemistry level in the brain” and the other wanted their providers outside of the PKU clinic to 
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be more informed on the actual impact of PKU on health, stating a need for “education for general 
practitioners that not all medical issues are PKU related.”  
There were no apparent trends when analyzing resource and support needs by geography, 
although only 29 out of the total 43 respondents provided the zipcode for their clinic, which was 
required for them to be included in this specific analysis (Figure 7). Even within California, which 
had the highest number of zipcodes provided (n=7), variations were noted between respondents. 
Two respondents (who both provided zipcodes for the same city) reported no additional support 
or resource needs, while the other five (two of whom also provided zipcodes for the same city 
noted above) did report either residual resource needs only (n=3) or both residual resource and 
support needs (n=2). One of these respondents said “Low protein food, drink has been good in CA, 
but moving,” suggesting no residual resource need at this time, while others in California 
commented on insurance needs. One respondent expressed challenges accessing resources, saying: 
My state has resources but requires information from doctors that I 
cannot get until I have the resources to see the doctor. 
As California was the only state with more than two known respondents, resource needs 
mentioned by California respondents were compared to responses from the rest of the United 
States. This comparison showed that the majority of respondents outside of California did not 
report residual needs (59-percent), compared to only 29-percent of respondents in California. The 
individuals outside of California who reported no residual needs included five taking pegvaliase 
and eight who were not, while the respondents in California who reported no residual needs were 
both taking pevalisase. Financial concerns were also more prominent outside of California, with 
three respondents explicitly stating financial concerns and three more stating residual needs 
regarding insurance coverage. 
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Figure 7 Distribution of reported zipcodes, grouped by state 
3.3.3.2 Neuropsychiatric Symptoms 
Three individuals were found to score 16 or lower (2 or more SD below the mean) on the 
cognition section. None of these individuals was taking pegvaliase, and they were all employed, 
non-students. Their phe levels varied, with one individual reporting phe levels in the 120-
360μmol/L range, another reporting levels of 361-600μmol/L, and the final individual reporting 
levels of 601-1,200μmol/. 
There was no significant difference between cognition or depression scores when 
comparing all respondents by pegvaliase status (taking versus not taking pegvaliase) or phe levels 
(below versus at or above 600μmol/L). However, when the three respondents who scored 16 or 
lower on the cognition section were excluded from the analysis, a significant difference became 
apparent for cognition by phe level (p=0.04). No other comparisons of neuropsychiatric symptoms 
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or quality of life  by either grouping were changed from significant to non-significant, or vice 
versa, following exclusion of these three individuals. Scores are summarized in Table 8. 
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Table 8 Summary of scores on Neuro-QOL short forms and comparisons by pegvaliase status and phe levels 
 




Neuro-QOL: Cognition Short Form 
Possible scores: 8-40 (median: 24)^ 
Pegvaliase 13 29.77  4.92 20-39 (19) 0.34 
(0.65) No Pegvaliase 28 27.64  7.61 12-40 (28) 
Phe <600μmol/L 27 29.56  6.99 12-40 (28) 0.067 
(0.04*) Phe ≥600μmol/L 14 25.93  6.21 14-38 (24) 
Neuro-QOL: Depression Short Form 
Possible scores: 14-70 (median: 24)^^ 
Pegvaliase 13 14.62  7.92 8-26 (18) 0.09 
(0.20) No Pegvaliase 27 18.26  8.36 8-31 (23) 
Phe <600μmol/L 27 16.48  7.83 8-31 (23) 0.47 
(0.45) Phe ≥600μmol/L 13 18.31  8.79 8-31 (23) 
^Higher score on Neuro-QOL Cognition Short Form = better cognitive functioning; ^^Lower score on Neuro-QOL Depression Short Form = less severe signs of 
depression; *p-value less than 0.05 
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3.4 Discussion 
The aim of this study was to begin to assess the impact of pegvaliase on several domains 
of life in individuals who take it, including changes in dietary management, impact on health-
related quality of life, improvements in neuropsychiatric functioning, and support and resource 
needs. The following sections discuss the results of this study, and how the findings may help to 
inform care for people who have PKU and future research needs in these areas. 
3.4.1 Impact of Pegvalise on Dietary Management and Phe Levels 
Across all respondents to the survey, the only individuals who had phe levels below 
120μmol/L were respondents who were taking pegvaliase, although one respondent who reported 
taking pegvaliase also reported phe levels of over 1,200μmol/L. The overall trend towards lower 
phe levels in respondents who are taking pegvaliase compared with other management approaches, 
although not significant, is consistent with another study which compared the effectiveness of 
pegvaliase to management involving low-phe diet alone or low-phe diet with sapropterin83. 
However, the majority of respondents taking pegvaliase reported that they had not experienced a 
significant change in their dietary protein intake (6/13 reporting no change; 3/13 reporting minimal 
change), which is interesting considering that most of the respondents taking pegvaliase had been 
taking it for at least a year, by which point dietary benefits would be anticipated. This, along with 
the finding that both length of time taking pegvaliase and reported phe levels were not associated 
with a statistically significant change in diet, suggests that decreases in phe levels did not 
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consistently translate to a significant change in diet. It is possible that some respondents had higher 
phe levels prior to starting pegvaliase due to consuming more protein than recommended. 
Additionally, some respondents may have experienced a substantial decrease in phe levels after 
initiating pegvaliase, but they started from a phe level high enough that even with a substantial 
decrease in phe levels, it was not possible to increase dietary protein appreciably. 
Regardless of these trends, there was an overwhelmingly positive response among 
respondents who shared the reasons for their change in diet following initiation of pegvaliase. A 
number of them commented on how their phe levels had improved, allowing for positive changes 
in the amount of protein they could consume. One respondent even stated directly that he/she had 
no regrets starting pegvaliase when it was still in clinical trials, emphasizing the positive changes 
that pegvaliase can offer many people who have classical PKU. Even among respondents who had 
not yet seen an improvement in phe levels, due to recently initiating pegvaliase, there seemed to 
be a significant amount of hope regarding the promise of pegvaliase. One respondent provided 
greater context to how increases in dietary protein can be beneficial, sharing a desire to feel more 
normal. By increasing the amount of dietary protein, respondents could be more like their peers in 
social settings, which was an important theme in later open-ended questions about support and 
resource needs as well.  
There were also improvements associated with pegvaliase that were not directly related to 
dietary changes but rather to other benefits related to decreased phe levels. One respondent detailed 
how they wanted the improved cognition, including stronger memory and greater mental clarity, 
that would come with improved control thorugh pegvaliase. Notably, this same respondent was 
forward-thinking, also sharing how important it would be to maintain this neurological function 
throughout life and well into older ages. 
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3.4.2 Factors in Quality of Life 
There appeared to be potential for improvement in overall self-perceived health among 
individuals taking pegvaliase compared to those who were not. However, the majority of 
respondents reported that their health was “good” or “excellent,” which is consistent with the 
literature90,91. Only four respondents of the total 43 reported their health was “poor” compared to 
others their age, none of whom were taking pegvaliase. However, phe level may play a role in this 
as well, as three of these four individuals had a phe level above 600μmol/L. These four individuals 
also consistently scored at or above the median possible score on each sub-section of the quality 
of life questionnaire that they completed (one respondent only completed the first three sub-
sections), suggesting a poorer quality of life among these four individuals in addition to perceiving 
their health to be poor. The only exception to this was the one respondent who had a phe level 
below 600μmol/L and scored just under the median possible score on the satisfaction with 
management sub-section.  
Specific significant differences were noted in the domains of satisfaction with 
management, general satisfaction with life and impact of PKU, when comparing by phe level. In 
contrast, only satisfaction with management was significant when comparing by pegvaliase status. 
Although this finding of improved satisfaction with management among respondents taking 
pegvaliase was expected due to the improvements in phe levels and dietary flexibity that can come 
with pegvaliase use, it is interesting in the context of the finding that respondents who were taking 
pegvaliase measured their phe levels significantly more often than respondents who were not. One 
of the questions in the management sub-section assessed satisfaction with the time it takes to 
manage PKU, and measuring phe levels regularly does require time. It may be that the improved 
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dietary flexibility, which minimizes the time-consuming planning and preparing of low-protein 
meals, outweighs the time that it takes to measure phe levels more regularly for these individuals. 
A significant difference in total quality of life score was only seen when comparing by phe 
level, not when comparing by pegvaliase status. This difference suggests that phe level may be a 
better predictor of quality of life than pegvaliase status alone, although the finding that pegvaliase 
status was significantly related to satisfaction with management may reflect the interplay between 
pegvaliase and lowering phe levels as co-dependent predictors of satisfaction. This suggests that 
pegvaliase may still be a defining factor in improving at least some aspects of quality of life for 
people who have classic PKU. This was difficult to assess thoroughly in the present study due to 
the limited sample size, especially because of the known interrelationship between pegvaliase use 
and phe levels26,27,29. It is also possible that there were greater differences when analyzing based 
on phe level compared to pegvaliase status because there were 18 respondents who had phe levels 
at or below 600μmol/L and were not taking pegvaliase, whereas only nine of the 13 respondents 
taking pegvaliase had phe levels at or below 600μmol/L, possibly lending more weight to the “low” 
phe group.  
Overall trends in quality of life scores between groups, although not statistically 
significant, showed respondents who were taking pegvaliase having better quality of life scores 
than those who were not, and respondents who have phe levels at or under 600μmol/L having 
better scores with those who have phe above 600μmol/L. This trend was seen in each sub-section 
individually, as well as in overall quality of life scores. This may suggest that both pegvaliase 
status and phe level are related to multiple domains of quality of life, although further research 
with a larger sample size is needed to determine to what extent this may be true. Further, the group 
of respondents who reported a phe above 600μmol/L, consistently averaged poorer quality of life 
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scores than any other grouping, again across all sub-sections and as compared to the total score. 
This sub-grouping was also the only one to have an average score on any sub-section that exceeded 
the median possible score. This occurred for three sub-sections: satisfaction with management, 
impact of PKU, and PKU-related worries, suggesting that these may be quality of life domains 
where people who have significantly elevated phe levels struggle the most.  
These findings are consistent with reports in the literature regarding the emotional costs of 
following a strict low-phe diet92, as well as the potential for feelings of anxiety or guilt surrounding 
having high phe levels and the financial costs of having a stricter diet90,91. Regarding the potential 
emotional costs of maintaining dietary restrictions, the management and impact sub-sections 
indirectly assessed this through questions about satisfaction with dietary flexibility, for which 
people who reported higher phe levels were not statistically more likely to report being less 
satisfied. However, responses to the question assessing this within the management sub-section 
did approach statistical significance. The impact sub-section also indirectly assessed the potential 
for emotional costs associated with dietary restriction through questions regarding a respondent’s 
ability to participate in general leisure activities and go out to eat, with the finding that people who 
reported lower phe levels were significantly more likely to report less impact on leisure activities. 
Further, only people who reported phe levels under 120 μmol/L consistently reported having no 
negative impacts. Regarding anxiety or guilt related to phe levels, a respondent’s satisfaction with 
their phe levels was assessed by the management sub-section, which showed that most people who 
reported phe levels above 600μmol/L were less satisfied with their phe levels. Finally, the impact 
of finances was assessed by the management and worries sub-sections, where again people who 
reported phe levels above 600μmol/L reported more issues with finances. This suggests that an 
inability to afford the cost of low-protein foods and medications necessary to decrease phe levels 
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is associated with increased worries. Notably, the only instance of another sub-group’s average 
score coming close to the median possible score was regarding satisfaction with management 
among the group of respondents not taking pegvaliase. This is consistent with the finding that the 
only significant difference seen in the quality of life assessment when comparing those taking 
pegvaliase to those not was in the sub-section assessing satisfaction with management.  
Trends were also noted in visually comparing average scores of respondents grouped by 
having phe levels at or under 600μmol/L and by their status as current users of pegvaliase, 
acknowledging that there is a high degree of overlap within these two groupings and that their 
average scores were often fairly similar. Even though the greatest number of significant differences 
in domains of quality of life were seen when comparing respondents reporting relatively low phe 
levels to respondents reporting relatively high phe levels, respondents taking pegvaliase typically 
had the best average score on each sub-section. The exception to this was the sub-section assessing 
worries related to PKU, in which respondents grouped by having phe levels at or under 600μmol/L 
scored slightly better than those grouped based on currently taking pegvaliase. It is also worth 
noting that the average scores for these two groups on the sub-section assessing the impact of PKU 
were essentially identical, with a difference of only 0.03 points, especially when standard deviation 
is taken into account. However, statistically speaking, phe level still seems to be the most 
significant factor impacting quality of life for adults who have PKU based on the finding of this 
study. This is interesting as it has been previously reported that increased protein intake is 
associated with improved quality of life in the context of diet-based management for PKU72. This 
does not align with having low phe levels unless a person is using pharmaceutical management 
approaches that allow for increased natural protein intake such as sapropterin or pegvaliase. 
However, the improvements seen in quality of life related to lower phe levels reported in this study 
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may be explained in part by the benefits of improved cognitive functioning in the presence of lower 
phe levels1,21.  
Non-significant differences were seen in the PKU-related worries and support sub-
sections. In both of these sub-sections, the average scores across all four groups (taking pegvaliase, 
not taking pegvaliase, phe at or under 600μmol/L, phe above 600μmol/L) were highly similar. This 
is consistent with the study by Douglas et al, on which the quality of life questionnaire used in the 
present study was based, as Douglas et al also did not find a significant difference in the worries 
or supports sub-sections.  
In the case of PKU-related worries, the scores all averaged close to the median possible 
score, indicating that there may be a greater negative impact on quality of life relating to worries 
surrounding PKU than other domains of quality of life, regardless of management approach or 
degree of phe control. Some of the worries respondents most commonly reported worrying about 
either “Often” or “All the Time” included worries about body image, finances, deciding whether 
to have children or being behind on having them, and potential for complications related to PKU. 
The diversity of these most common worries emphasizes how much PKU can impact those who 
are affected by it and affects many areas of their lives. Certain ones – namely financial concerns 
and uncertainty surrounding having children – were mentioned in several open-ended responses 
on resource and support needs as well.  
Regarding satistfaction with support, each of the averages was close to eight points, 
suggesting that respondents were overall satisfied on average with the supports they received from 
their family, friends, doctor, and dietician, again regardless of management approach used or level 
of phe control. There was variation among respondents on whether each respondent was more 
satisfied with social supports (family or friends) compared to clinical supports (doctor or dietician). 
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This suggests that although a desire for adult-focused clincal care was reported by respondents and 
also previously reported in the literature55,59, it does not detract from satisfaction with their current 
clinical care team. Rather, it suggests adult-based clinical care may be a preferred care setting.  
Quantitative assessment of quality of life in the present study is partially consistent with 
the results from the study by Douglas et al which developed the quality of life questionnaire on 
which the present study’s survey was based. As was seen in the present study with respondents 
taking pegvaliase, Douglas et al saw a significant improvement regarding satisfaction with 
management among sapropterin-responders20. However, they also saw improvements among 
sapropterin-responders regarding the impact of PKU and overall quality of life20. Significant 
differences in these domains were only seen in the comparisons by phe level in the present study, 
not in comparisions by pegvaliase status. The significantly better scores among respondents with 
phe levels at or below 600μmol/L compared to those with phe levels above 600μmol/L on sub-
sections about satisfaction with management and impact of PKU are consistent with the study by 
Douglas et al, though, as that study also saw improvements on management scores and impact 
scores related to lowered phe levels and increased phe tolerance20. Interestingly, the study by 
Douglas et al did not find any significant differences in quality of life by phe level prior to initiation 
of sapropterin. This does not directly contradict the findings of the present study regarding the 
impact of phe level on quality of life because most of the respondents in this study were using 
pegvaliase or sapropterin at the time of survey and quality of life was assessed at a single point in 
time, instead of correlating changes in phe level with improvements in quality of life over time. 
However, this finding by Douglas et al is interesting to note as it supports the changes caused by 
a pharmaceutical approach – in this case, sapropterin – being more impactful than baseline phe 
76 
level on quality of life, warranting further research into the impacts of phe levels compared to 
pegvaliase use.  
These differences in results are likely due the differences in study structure, as essentially 
the same questionnaire was used for quantitative assessment of quality of life. The study by 
Douglas et al utilized a longitudual approach, tracking changes in quality of life from baseline to 
a year after initiation of sapropterin20. In contrast, the present study was cross-sectional and 
compared people who are taking pegvaliase and those who are not, without excluding people who 
use other approaches for managing their PKU, including a variety of combinatory approaches used 
by respondents both taking and not taking pegvaliase. Sample size was similar in both studies. 
Another important consideration in comparing the study by Douglas et al to the present 
study is how the side effects of pegvaliase impact quality of life. Although the majority of 
respondents taking pegvaliase reported that they were either not experiencing side effects of 
pegvaliase or were experiencing side effects that had no impact on their quality of life, the potential 
side effect profile of pegvaliase is not negligible, especially in the first several months following 
initiation. These can include hypersensitivity reactions such as injection site reactions, rashes, or 
joint point, as well as a risk for anaphylaxis, although most adverse reactions reported were still 
mild to moderate27,81. In contrast, sapropterin has a relatively benign side effect profile. In clinical 
trials, the majority of adverse events were mild to moderate, with the only significant adverse event 
being deemed unrelated to sapropterin, and the most common effects were headache, diarrhea, and 
abdominal pain94. These contrasting side effect profiles are important to consider when examining 
the potential impacts different management approaches can have on quality of life. 
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3.4.3 Neuropsychiatric Impact 
No significant differences were found when comparing cognitive functioning or depressive 
symptoms among respondents who are and are not taking pegvaliase, even though there is evidence 
in the literature to support pegvaliase being associated with improved neuropsychiatric outcomes 
after initiation of pegvaliase. During clinical trials, it was found that patients who were taking 
pegvaliase had better executive functioning skills, including working memory, cognitive 
flexibility, and inhibitory control, as well as better attention compared to other patients who were 
taking a placebo or compared to themselves at baseline prior to initation of pegvaliase26,31. In 
addition to the small sample size and cross-sectional nature of this study, it is possible that the 
present study did not see evidence of improved cognition among respondents who were taking 
pegvaliase compared to those who were not because attention was only assessed by a sub-set of 
the questions asked on the Neuro-QOL cognition short form. As improved attention is a previously 
established benefit following initiation of pegvaliase, a questionnaire more focused on attention 
may have been better able to identify a difference in cognition. Executive function, the other area 
of cognition shown to improve with pegvaliase in clinical trials, also could not be assessed with 
the Neuro-QOL cognition short form due to the limited question content of this standardized 
assessment. The sampling approach used in this study may also have limited the ability to detect a 
difference, as people with higher cognitive functioning may have been more likely to complete the 
survey. 
Interestingly, a significant difference was noted when comparing by phe level with 
exclusion of the three respondents who scored 16 or lower on the Neuro-QOL cognition short 
form. This may have been because each of these three individuals reported different ranges of phe 
levels (120-360μmol/L, 361-600μmol/L, and 601-1,200μmol/L), potentially confounding the 
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comparison by phe levels, and none of them was taking pegvaliase, which could have minimized 
the impact on the comparison by pegvaliase status. Additionally, the self-report nature of this study 
may also have skewed the data and contributed to this unexpected result. However, the finding 
that lower phe level, is associated with better cognitive functioning is consistent with findings from 
the clinical trials on pegvaliase as well, as these trials found improved attention as a result of the 
improved phe levels that resulted from pegvaliase treatment26,31.  
The lack of a significant difference regarding depressive symptoms in any comparison, 
with or without the three individuals with low scores on the cognition section, may be explained 
by the length of time it takes for improvements in mood to occur following initiation of pegvaliase. 
Specifically, no improvements in mood were seen during the randomized control trial, which lasted 
only eight weeks, but improvements were seen in the initial phase three trials, which lasted two 
years. Approximately half of respondents taking pegvaliase in this study had initiated it less than 
a year prior to taking the survey, suggesting that enough time may not have passed to allow these 
particular benefits of pegvaliase to take effect, and making it even more challenging to detect a 
significant improvement in the few respondents who had been taking pegvaliase for a year or more. 
3.4.4 Supports and Resources 
There were no significant differences reported in the satisfaction with support sub-section 
of the quality of life questionnaire. This was consistent with the non-significant differences in the 
number of respondents reporting residual resource needs between the pegvaliase and no pegvaliase 
sub-groups. However, there did seem to be a pattern for people taking pegvaliase reporting fewer 
residual resource and support needs. 
79 
Several of the residual needs that were reported by respondents have previously been 
reported in the literature as well. One example is the need for adult-specific clinical settings for 
PKU identified by a study respondent on both the question assessing residual support needs and 
the question assessing residual resource needs. Barriers to accessing care for PKU as an adult have 
been reported in the literature, with some adults encountering difficulty finding care at all and 
others preferring to be seen in an adult-focused setting as opposed to the pediatric clinics where 
they were seen as children55,59. The financial impact of PKU, which was prevalent in responses to 
both the question about residual support needs and residual resource needs among respondents 
taking and not taking pegvaliase, has also been reported in the literature, especially for adults, due 
to the tendency of states to not provide financial support for medical formulas and foods for adult 
patients55,63. This dearth of financial support for adults who have PKU who are trying to purchase 
medical foods and specialized formulas in many states likely explains why finances and financial 
management, along with insurance, were a prevalent topic in the survey responses. 
This study also identified unique residual resource needs regarding social supports intended 
for adults who have PKU. This was the first time social supports intended for adults, including 
support groups, opportunities to discuss maternal PKU experiences, and the difficulties navigating 
certain social settings given the dietary restrictions that are traditionally a key part of PKU 
management, are reported. Previous studies on residual needs for adults, as mentioned above, have 
primarily found these needs to be related to adult-focused clinics55,59, not adult-focused social 
supports and resources.  However, need for social supports in general, and feelings of isolation 
which can be addressed through improved social supports, have been reported71. These previously 
reported feelings of isolation seem to stem from the stigma surrounding PKU, related to the 
difficulty many respondents experienced in navigating complex social situations, and feeling 
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unable to explain PKU to others in a way that is understandable71. This latter point seems especially 
pertinent to the respondent who mentioned not knowing who to talk to about her maternal PKU 
experiences. Overall, filling these social support and resource needs is likely a critical part of 
improving quality of life for people, especially adults, who have PKU, as social relationships are 
a key component of quality of life72. The importance of social social supports was further 
reinforced by responses to the select-all-that-apply question about types of support provided by 
individuals other than the respondent’s doctor, dietician, family, and friends, which predominantly 
focused on emotional support (n=23) and was closely followed by social support (n=21).  
It was not possible to identify geographic trends regarding these residual resource and 
support needs due to the small number of respondents who provided a zipcode to be included in 
this analysis. However, there was preliminary evidence for a trend involving more financial needs 
outside of California. As mentioned above, it is well-known that financial supports, at minimum, 
vary by state, although this variation is less prevalent for adult patients due to almost universal 
lack of state-based support for adults who need specialized medical foods or formulas55. Upon 
closer look at California, as the state with the largest number of zipcodes reported, respondents 
seemed to have differing experiences. This is to be expected to an extent as each respondent is a 
unique adult who has a unique set of needs. One respondent in California explicitly said that the 
medical food and formula supports in California were good, while another respondent stated a 
need for better resources regarding insurance, suggesting that not all Californians may be equally 
able to access these resources. Also, there was the respondent who was trapped in a resource loop 
– unable to see the doctor without resources, but unable to access resources without first seeing a 
doctor – further emphasizing potential accessibility issues, even in states, like California, known 
to have relatively good supports and resources in place for people who have PKU. 
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For resources utilized by respondents, the most common resource reported was NPKUA 
(n=27), which is to be expected as the NPKUA patient registry was the main source of recruitment 
for this study. Support groups via social media or other online services were the next most 
commonly reported (n=23), with in-person support groups only being reported by two respondents. 
It is not clear from the survey responses if online support groups are more commonly used than 
in-person options in general, which could be the case due to PKU being a rare disease, or if these 
responses were skewed due to the survey being conducted in the midst of a pandemic where fewer 
in-person options would have been available. Also notable was the fact that NORD, which does 
offer patient assistance programs, was the third most commonly used resource (n=18), while co-
pay assistance programs (n=3) and care coordination services (n=2) through BioMarin – the 
pharmaceutical company that produces sapropterin and pegvaliase – were far less commonly used. 
Medical assistance (n=3) and assistance from the state newborn screening program (n=5) were 
also among the less commonly used resources, although the latter is expected based on respondents 
being adults, many of whom would have aged out of such services55. The resources commonly 
utilized – and those not as commonly utilized – do suggest an important disconnect between 
exisiting resources and patients being aware of them and able to access them. For example, social 
supports and resources were commonly mentioned in the open-ended questions assessing residual 
needs, even though many respondents reported participating in support groups in the select-all-
apply-question about utilized resources. Perhaps, as mentioned by a few respondents, there are not 
as many support groups that meet their needs as adults, as compared to support groups for children 
who have PKU or families. There is also the issue of finances, which was mentioned by many 
respondents, even though financial assistance programs through NORD and BioMarin exist. While 
it is possible that the individuals reporting needs related to finances or financial management are 
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not eligible for these programs based on income-level and/or management approach, it is also 
possible that these respondents are not aware that these programs exist or are aware of them but 
are unsure how to access them. These potential social and financial resources suggest that adults 
who have PKU could benefit from additional conversations with their providers or other members 
of the PKU community to help them learn about such resources that could benefit them by meeting 
their residual needs. 
3.4.5 Limitations & Future Directions 
The ability of the present study to identify significant aspects of quality of life, dietary 
management, neuropsychiatric functioning, and resource and support needs was limited by the 
sample size. This is exacerbated by the small number of people taking pegvaliase in the sample, 
especially those who have been taking it long enough to see a positive impact on phe levels and 
protein tolerance, relative to the total sample size. In addition, not all respondents completed the 
survey in it’s entirely, although all did complete the majority of the survey. Qualitative analysis 
was also limited due to the majority of respondents offering brief responses to the open-ended 
questions and many more respondents skipping those questions entirely. Also, due to the small 
sample size, respondents who were using multiple management approaches, including pegvaliase 
in conjunction with sapropterin and dietary management, were not excluded, which may have 
made distinctions in quality of life between the sub-group taking pegvaliase and the sub-group not 
taking pegvaliase less apparent. It was also not possible to determine causation due to the cross-
sectional nature of this study, as well as the self-report nature of the questionnaire and the potential 
for sampling bias due to the relatively passive recruitment methods used. It must also be considered 
that the self-reported phe levels, which were a critical aspect of the quality of life and 
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neuropsychiatric data analyses, may have been affected by response bias if respondents reported 
lower phe levels than their actual average levels, which would have affected the overall statistical 
analysis. 
With these limitations in mind, this study is the first to investigate the impact of pegvaliase 
on quality of life and support and resource needs. As such, the preliminary evidence presented here 
can be used to aid in the development of future studies collecting more direct data by tracking any 
improvements in quality of life and residual resource and support needs over time in the same 
participants following initiation of pegvaliase. This could be done using a structure similar to the 
study on the impact of sapropterin on quality of life by Douglas et al20, or limiting participants to 
those managing their PKU with pegvaliase, with or without dietary management, sapropterin with 
dietary management, or dietary management alone, as was done by Zori et al in their investigation 
of the effectiveness of each of these approaches in lowering phe levels.83 
3.5 Conclusions 
The preliminary data collected by the present study provide insight into potential factors 
that influence quality of life for people who have PKU and which domains of quality of life may 
be most likely to be impacted for affected individuals. Specifically, these domains seem to be 
satisfaction with management, which is likely modifiable by management approach and phe level, 
and worries related to PKU. Phe level is also likely to be the strongest influence on quality of life, 
regardless of management approach used to achieve low phe levels, as phe level was shown to 
have a significant impact on satisfaction with life in general, the impact of PKU, and total quality 
of life score, in addition to satisfaction with management. This is consistent with the well-
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established relationship between low phe levels and quality of life related to alleviation of 
symptoms associated with increased phe levels in adulthood, especially in regard to promoting 
mental clarity and function1,21, as noted by one respondent taking pegvaliase in an open-ended 
response. Further research is indicated to determine how the effects of PKU-related worries can 
be addressed, as worries were high among all comparison groups.  
This study also provides insights into reasons why people who have PKU change their 
dietary protein intake in response to increased phe tolerance and what residual support and resource 
needs still exist, even when phe tolerance is greatly improved. Most of the respondents taking 
pegvalise who shared their reason for changing their diet cited a positive change or benefit, 
including improved phe control, a more normal life, improved day-to-day life, and better mental 
clarity and memory. Respondents taking pegvaliase also appeared to have fewer residual resource 
and support needs. Even when residual needs were reported by respondents taking pegvaliase, 
these needs were focused on finances, compared to the constellation of residual needs – including 
primarily financial, social, and adult-focused resources and supports – reported by respondents 
who were not taking pegvaliase.  Special attention should be paid to adult-focused social supports, 
as many respondents cited a need for either social supports in general or social supports for 
situations unique to adults who have PKU. This included adult-focused social support needs of 
adults who have PKU being reported for the first time. In comparing the residual needs that were 
reported to the utilized resources that were reported, it appears there is a disconnect between 
supports and resources that exist and patients’ ability to consistently access them. This was seen 
in both social and financial support areas. This could be happening because many adults who have 
PKU are unaware of these resources or are unsure of how to access them. Alternatively, it may be 
that not all adults who could benefit from these resources and supports are eligible for them. 
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Regardless, it will be important to work towards improving access to these key resources and 
supports for adults who have PKU. 
Evidence presented here supports worries surrounding PKU as a crucial factor in quality 
of life for people who have PKU which may not be ameliorated by existing treatments or lowered 
phe levels alone. Several of these worries were also noted through responses to open-ended 
questions regarding resource and support needs, thus, more clearly defining and addressing these 
worries may be a better way to improve quality of life. The impact of satisfaction with management 
is also noteworthy, as this seems to be an area of quality of life that can be addressed with improved 
treatments that help to decrease phe levels and improve phe tolerance, especially as this area was 
seen to have a significant difference when comparing scores by both pegvaliase status and phe 
levels. This was reinforced through analysis of the open-ended questions inquring about reasons 
for changes in dietary protein and the overall positive feedback from respondents who were already 
experiencing positive changes due to pegvaliase and the hopes other respondents had for the 
promise of positive changes to come now that they had access to pegvaliase.  
Although there are limitations, the study provides preliminary evidence regarding key areas 
of quality of life in adults who have PKU, including general domains of quality of life, as well as 
assessments of neuropsychiatric symptoms and existing gaps in resources and supports. It was the 
first to do so with a focus on the impact of pegvaliase and found evidence of unique residual needs 
that had not been previously reported in the literature. The nuances gleaned from the quality of life 
assessment and thematic analysis can contribute to providers’ awareness of the interests, worries, 
and needs of the patients who have PKU for whom they provide care, which may in turn help to 
further promote quality of life for these individuals. 
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4.0 Relevance to Genetic Counseling and Public Health 
The overall goal of this study was to explore the impact of pegvaliase, compared to other 
management approaches, on the quality of life and resource needs of individuals who have PKU. 
This has the potential to improve care for people who have PKU by identifying gaps in support 
and ways to promote their quality of life. The knowledge gained by this study can inform all 
providers in a PKU clinic, including nurses, dietitians, physicians, and genetic counselors, about 
how they interact with and care for their patients.  
As PKU is one of the most common inherited metabolic disorders,1 the information learned 
from this study has the potential to benefit a significant number of people. This study is further 
relevant to public health as it aligns with two of the 10 Essential Public Health Services: 1) assess 
and monitor population health status, factors that influence health, and community needs and 
assets, 2) communicate effectively to inform and educate people about health, factors that 
influence it, and how to improve it95.  The survey addresses the first essential service by assessing 
factors that influence health and community needs and assets among people who have PKU by 
inquiring about their PKU management, quality of life, mental health, current supports, and 
residual resouces needs. This then relates to the latter service as information can inform both health 
care providers and people who have PKU, providing these individuals with the knowledge to 
influence and improve patients’ health, related to having PKU. 
Information gained from this study includes the benefits of pegvaliase in improving 
satisfaction with management and potentially other domains of quality of life. As pegvaliase use 
and phe control are often closely related, the benefits in quality of life related to general satisfaction 
with life and the impact of PKU seen by respondents who have lower phe levels, may also be 
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applicable to people who utilize pegvaliase. It will also be important for providers to be aware of 
the potential impacts of PKU-related worries on quality of life, as this is a survey section in which 
all comparison groups scored relatively poorly. This may involve spending time in an appointment 
assessing what a patient’s worries might be related to their PKU and working to address those in 
a collaborative manner. Key gaps in resources and supports, such as financial needs and resources 
tailored to adult patients, as well as medical and social needs are also important for providers, or 
in the case of social supports – the PKU community and organizations at large – to spend time 
addressing, as is often already done by members of the PKU health care team.. 
In relation to genetic counseling specifically, the knowledge gained by this study will be 
useful in providing patients and families with anticipatory guidance and supportive counseling to 
address their psychosocial needs. As the first study on quality of life among people who have PKU 
who are taking pegvaliase, this information will help provide preliminary answers as to how new 
treatments for PKU can improve quality of life. This relates to a number of the Practice-Based 
Competenies for Genetic Counselors established by the Accreditation Council for Genetic 
Counselors (ACGC): “Effectively educate clients about a wide range of genetics and genomics 
information based on their needs, their characteristics and the circumstances of the encounter,” 
“Integrate knowledge of psychosocial aspects of conditions with a genetic component to promote 
client well-being,” and “Demonstrate the skills necessary to successfully manage a genetic 
counseling case”96. This is important because a genetic counselor’s role extends beyond solely 
explaining the genetic basis and inheritance of PKU; it encompasses addressing psychosocial 
concerns, such as questions regarding quality of life, mental health, and resources, for patients and 
their families, as well. In short, the results of this study can begin to help genetic counselors 
accurately and effectively educate patients who have PKU on the impact pegvaliase can have on 
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quality of life, available resources that patients have reported to be helpful, and areas where 
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Appendix B Survey Content and Structure 
PKU QoL Thesis 
 
 
Start of Block: Default Question Block 
 
If you are an adult (18 years or older) with phenylketonuria (PKU)…     I am inviting you to take 
part in a research study that is part of my training to become a genetic counselor. My name is 
Trinity Sprague, and I am a student at the University of Pittsburgh Graduate School of Public 
Health. I am interested in learning more about 1) how living with PKU affects your “quality of life” 
(your health, comfort, and happiness), and 2) if you have unmet support or resource needs. To 
do this, I am working with the UPMC Children’s Hospital of Pittsburgh and the National PKU 




This survey will ask about: 
- If you are happy with how you are managing your PKU 
- The impact of PKU on your life 
- Your satisfaction with the resources and support you use and receive 
- How happy you are with your health and your quality of life 
- Your thinking skills and if you have any feelings related to depression.  
 
 
We will compare answers from people who are taking pegvaliase (brand name: Palynziq), a 
medication that has been approved for people with PKU who have not responded to previous 




We hope to share the results of this study with medical providers who care for people who have 
PKU. Risks of participating in this study are limited but may include negative feelings due to 
answering some of the questions. If you have negative feelings or other distress while taking the 
survey, you should contact your primary care provider or other health professional. There are no 
direct benefits to you for participating in this study. If you choose to participate, your responses 
will be confidential and anonymous. This means we will store your responses securely and your 
responses will not be linked to you in any way. Your participation is optional, and you may 
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withdraw from this study at any time. Any responses you provide prior to withdrawing will be 
used by the study team. Your decision on whether to participate will have no effect on future 




This study is being conducted by myself, Trinity Sprague, and you can reach me at 
spraguet@upmc.edu. You can also contact my mentor, Cate Walsh Vockley, MS, LCGC, a 
genetic counselor at Children's Hospital of Pittsburgh, at catherine.walshvockley@chp.edu if 
you have any questions or concerns about this study. Thank you for considering participating in 
this study. If you are interested in taking the survey, please click the arrow below to begin. 
 
 




Before you begin the survey, please answer the next two questions to confirm that you are 




Are you 18 years of age or older? 
oYes  (1)  
oNo  (2)  
 
Skip To: End of Survey If Are you 18 years of age or older? = No 
 
 
Do you have phenylketonuria (PKU)? 
oYes  (1)  
oNo  (2)  
 
Skip To: End of Survey If Do you have phenylketonuria (PKU)? = No 
 




Thank you. You are eligible to complete the remainder of this survey. The next set of questions 




What was your average Phe level over the last month (the last 30 days)? 
oLess than 120 umol/L (Less than 2 mg/dL)  (1)  
o120 - 360 umol/L (2 - 6 mg/dL)  (2)  
o361 - 600 umol/L (6.01 - 10 mg/dL)  (3)  
o601 - 1,200 umol/L (10.01 - 20 mg/dL)  (4)  




How often do you typically measure your Phe level? 
oLess than once a month  (1)  
oOnce a month  (2)  
oOnce a week  (3)  





Are you currently taking pegvaliase (Palynziq) for your PKU? 
oYes  (1)  
oNo  (2)  
 
 
Display This Question: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
 
How long have you been taking pegvaliase (Palynziq) for your PKU? 
oLess than 6 months  (1)  
o6 months - Less than 9 months  (2)  
o9 months - Less than 1 year  (3)  
o1 year or more  (4)  
 
 
Display This Question: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = No 
 
Have you ever taken pegvaliase (Palynziq) for your PKU? 
oYes  (1)  
oNo  (2)  
 
 
Display This Question: 
If Have you ever taken pegvaliase (Palynziq) for your PKU? = Yes 
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How long did you take pegvaliase (Palynziq) for your PKU? 
oLess than 6 months  (1)  
o6 months - Less than 9 months  (2)  
o9 months - Less than 1 year  (3)  
o1 year or more  (4)  
 
 
Display This Question: 
If Have you ever taken pegvaliase (Palynziq) for your PKU? = Yes 
 
 






Please select any other ways you manage your PKU. You may select more than one. 
▢Kuvan (also known as sapropterin or BH4)  (1)  
▢Diet/formula  (2)  
▢Other:  (3) ________________________________________________ 








The following section will focus on your quality of life (your health, comfort, and happiness). It 
will start with questions that ask you to think more generally.  
    
Compared with others your age, would you say your health is: 
oExcellent  (1)  
oGood  (2)  
oFair  (3)  




Are you currently a student? 
oYes  (1)  




Are you currently employed? 
oYes  (1)  





This set of questions will focus on your satisfaction with your life in general. Please rate your 
answer to each question on a scale of 1 (very satisfied) to 5 (very unsatisfied) using the table 
below. 
Display This Choice: 
If Are you currently a student? = Yes 
Or Are you currently employed? = Yes 
Display This Choice: 
If Are you currently a student? = Yes 
Or Are you currently employed? = Yes 
Display This Choice: 
If Are you currently a student? = Yes 















are you with 
your sleep? 
(1)  
o o o o o 
How satisfied 






o o o o o 
How satisfied 




o o o o o 
Display This 
Choice: 
If Are you 
currently a 






are you with 
your 
performance 
in school or 
at work? (3)  




If Are you 
currently a 






are you with 
your 
attendance in 
school or at 
work? (4)  
o o o o o 
Display This 
Choice: 
If Are you 
currently a 










treat you? (5)  
o o o o o 
How satisfied 
are you with 
your ability to 
complete 
household 
activities? (6)  
o o o o o 
How satisfied 
are you with 
the 
appearance 
of your body? 
(7)  
o o o o o 
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How satisfied 
are you with 




o o o o o 
How satisfied 
are you with 
your leisure 
time? (9)  
o o o o o 
How satisfied 
are you with 
life in 
general? (10)  




Page Break  
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This set of questions will focus on your satisfaction with how you manage your PKU. Please rate 
















are you with 
the amount 
of time it 
takes to 
manage your 
PKU? (1)  
o o o o o 
How satisfied 






o o o o o 
How satisfied 
are you with 





o o o o o 
How satisfied 
are you with 




level? (4)  
o o o o o 
How satisfied 




level? (5)  
o o o o o 
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How satisfied 










o o o o o 
How satisfied 








o o o o o 
How satisfied 








o o o o o 
How satisfied 
are you with 
the 
assistance 
you get from 




o o o o o 
How satisfied 




has on your 
family? (10)  
o o o o o 
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How satisfied 




PKU? (11)  
o o o o o 
How satisfied 





o o o o o 
How satisfied 




o o o o o 
How satisfied 
are you with 
the flexibility 
you have in 
your diet? 
(14)  




Display This Question: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
Or Have you ever taken pegvaliase (Palynziq) for your PKU? = Yes 
 
How has your diet changed since you started taking pegvaliase (Palynziq)? 
oMy diet hasn't changed  (1)  
oMy protein intake has changed a little  (2)  




Display This Question: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
Or Have you ever taken pegvaliase (Palynziq) for your PKU? = Yes 
 




Display This Question: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
Or Have you ever taken pegvaliase (Palynziq) for your PKU? = Yes 
 
How much have the side effect(s) of pegvaliase (Palynziq) impacted your quality of life 
(your health, comfort, and happiness)?  
oSignificantly  (1)  
oModerately  (2)  
oSlightly  (3)  
oI am experiencing side effect(s) of pegvaliase (Palynziq), but they are not affecting my 
quality of life at all.  (4)  
oI am not experiencing side effect(s) of pegvaliase (Palynziq).  (5)  
 
 
Page Break  
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This set of questions will focus on the impact of your PKU on your daily life. Please rate your 
answer to each question on a scale of 1 (never) to 5 (all the time) using the table below. 
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How often do you have a bad 
night's sleep? (3)  
o o o o o 
How often does your PKU 
interfere with your family life? 
(2)  
o o o o o 
How often do you find your 
PKU limiting your social 
relationships and 
friendships? (4)  
o o o o o 
How often do you feel 
restricted by your diet? (5)  
o o o o o 
How often do you miss work, 
school, or household duties 
because of your PKU? (6)  
o o o o o 
How often do you find 
yourself explaining what it 
means to have PKU? (7)  
o o o o o 
How often do you think that 
your PKU interrupts your 
leisure-time activities? (8)  
o o o o o 
How often are you teased 
because you have PKU? (9)  
o o o o o 
How often do you find you 
eat something you shouldn’t 
rather than tell someone that 
you have PKU? (10)  
o o o o o 
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How often do you find that 
your PKU prevents you from 
going out to eat with your 
friends? (11)  
o o o o o 
How often are you 
embarrassed by having to 
deal with your PKU in public? 
(1)  
o o o o o 
How often do you feel that 
your PKU limits your ability to 
do other things that interest 
you (for example: playing a 
sport, volunteering in your 
community)? (12)  
o o o o o 
How often do you find that 
your 
parents/spouse/friend/relative 
are too protective of you? 
(13)  
o o o o o 
How often do you feel that 
your 
parents/spouse/friend/relative 
worry too much about your 
PKU? (14)  
o o o o o 
How often do you find that 
your 
parents/spouse/friend/relative 
act like PKU is their disease, 
not yours? (15)  




Page Break  
 
This set of questions will focus on the worries you might have surrounding your PKU. Please 
rate your answer to each question on a scale of 1 (never) to 5 (all the time) using the table 
below. 
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All the Time 
(5) 
How often do 
you worry 






status of your 
current 
marriage? (1)  
o o o o o 
How often do 
you worry 
that PKU will 
affect 
whether you 





children? (2)  
o o o o o 




will not get a 
job you want 
due to PKU? 
(3)  
o o o o o 
Display This 
Choice: 
If Are you 
currently a 
student? = Yes 
How often do 
you worry 
that PKU will 
affect 
whether you 





o o o o o 
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o o o o o 
How often do 
you worry 




PKU? (6)  
o o o o o 










o o o o o 
Display This 
Choice: 
If Are you 
currently a 
















o o o o o 
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How often do 
you worry 
that because 









parties? (9)  
o o o o o 
How often do 
you worry 
that because 





children? (11)  
o o o o o 


















The following questions will ask about your current resources and supports, as well as areas 




This set of questions will focus on your satisfaction with the supports you receive for your PKU. 
Please rate your answer to each question on a scale of 1 (very satisfied) to 5 (very unsatisfied) 



















o o o o o 
How satisfied 





o o o o o 
How satisfied 





o o o o o 
How satisfied 

















What kind of support do they provide? You may select multiple options. 
▢Emotional  (1)  
▢Social  (2)  
▢Medical  (3)  
▢Financial  (4)  
▢Other:  (5) ________________________________________________ 
▢No one (other than my family, friends, doctor, and/or nutritionist) provides me with 










Which of the following resources do you use? You may select multiple options. 
▢National Organization for Rare Disorders (NORD)  (1)  
▢National PKU Alliance (NPKUA)  (2)  
▢Medical Assistance  (3)  
▢Newborn Screening Program Assistance  (4)  
Display This Choice: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
▢BioMarin Care Coordination Services  (5)  
Display This Choice: 
If Are you currently taking pegvaliase (Palynziq) for your PKU? = Yes 
▢BioMarin Co-Pay Assistance  (6)  
▢Low-protein recipe resource (for example, Cookforlove.org)  (7)  
▢Online Phe-tracker (for example, HowMuchPhe.org)  (8)  
▢In-person support groups  (9)  
▢Online/social media-based support groups  (10)  





Are there any other resources (information, assistance, materials, other) that you need but have 
not been able to get? 
oYes  (1)  












PKU often affects people’s ability to think and can impact their emotions. The following 
questions explore how pegvaliase (Palynziq) might impact these areas of health compared to 




This set of questions will focus on your ability to think. Please respond to each question or 
statement by marking one box per row. 
 
 
In the past 7 days... 
 Never (1) 
Rarely 
(once) (2) 




a day) (4) 
Very Often 
(several 
times a day) 
(6) 




it. (1)  
o o o o o 
My thinking 
was slow. (2)  
o o o o o 
I had to work 
really hard to 
pay attention 
or I would 
make a 
mistake. (3)  
o o o o o 
I had trouble 
concentrating. 
(4)  






How much DIFFICULTY do you currently have... 
 None (1) A little (2) 
Somewhat 
(3) 
















that are not 
part of your 
weekly 









o o o o o 
managing 
your time to 
do most of 
your daily 
activities? (3)  

















This set of questions will focus on any feelings you might have related to depression. Please 
respond to each question or statement by marking one box per row. 
 
 





 Never (1) Rarely (2) 
Sometimes 
(3) 




o o o o o 
I felt 
hopeless. (2)  
o o o o o 
I felt that 
nothing could 
cheer me up. 
(3)  
o o o o o 
I felt that my 
life was 
empty. (4)  
o o o o o 
I felt 
worthless. (5)  
o o o o o 
I felt 
unhappy. (6)  
o o o o o 
I felt I had no 
reason for 
living. (7)  
o o o o o 

















Thank you for taking the time to complete our survey. To finish, please enter the zip code for the 
PKU clinic where you receive care (NOT your home zip code). This is so that we can 
compare unmet resource and support needs across the country. 
________________________________________________________________ 
 




Appendix C Permissions 
Appendix C.1 PKU-QOL Permission 
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Appendix D Informational Paragraph/Flyer 
 
Q ua lity  of Life  a nd Resource N eeds Follow ing Trea tment of PKU w ith 
Pegva lia se (Pa lynziq)  
 
* *  Are you an adult (18 years or older) with phenylketonuria (PKU)? * *  
 
 
My name is Trinity Sprague, and I am a graduate student working on my master’s degree in Genetic Counseling 
at the University of Pittsburgh.  
 
I am interested in learning more about how taking pegvaliase (Palynziq) can impact the lives of people who have 
PKU. To do this, I have developed a survey to ask people who have PKU about their satisfaction with their PKU 
management and their access to supports and resources, as well as the impact of their PKU on their quality of life. 
A person’s quality of life includes their health, comfort, and 
happiness. 
 
If you a re a n a dult w ho ha s PKU, you ma y  be eligible  
for this study , even if you ha ve never ta k en 
pegva lia se. 
 
To find out more about the questionnaire and to participate,  
please follow the link below: 
https:/ / pitt.co1.qualtrics.com/ jfe/ form/ SV_cPkvZeZgxA8GXFH 
 
If you have questions or concerns about this research study,  
please contact me at: spraguet@upmc.edu 
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Appendix E Scoring Protocols 
Appendix E.1 Quality of Life Sub-Sections 
Appendix Table 1 Scoring Scheme for General Satisfaction with Life, Satisfaction with Management, and 
Satisfaction with Support 
Response Option Score 
Very Satisfied 1 
Somewhat Satisfied 2 
Neutral 3 
Somewhat Unsatisfied 4 
Very Unsatisfied 5 
 
 
Appendix Table 2 Scoring Scheme for Impact of PKU and PKU-Related Worries 





All the Time 5 
126 
Appendix E.2 Neuro-QOL Short Forms 
Appendix Table 3 Scoring Scheme for Cognition Short Form 
 Response Choice Score 
“In the past 7 days…” 
Questions 
Never 5 
Rarely (once) 4 
Sometimes (2-3 times) 3 
Often (once a day) 2 
Very often (several times a day) 1 
“How much difficulty do 
you currently have…” 
Questions 
None 5 
A little 4 
Somewhat 3 
A lot 2 
Cannot do 1 
 
 
Appendix Table 4 Scoring Scheme for Depression Short Form 
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